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ABSTRACT 
Cancer is characterised by the unconstrained growth of cancerous cells, which damages 
the healthy cells and ultimately the tissue of the host.  Chemotherapy forms an essential 
component in the treatment of this disease, however most anti-tumour drugs suffer from 
various deficiencies, e.g. increased toxicity, reduced serum half life and poor water 
solubility.  The focus of this project was to address some of these deficiencies by 
conjugating selected drugs to a water-soluble polymeric carrier.  
 
Selected water-soluble biodegradable carriers were synthesized.  Copolyaspartamides, 
polyamidoamines and polyamides were obtained by condensation polymerisation, 
Michéaltype addition polymerisation and ester amine base-catalysed polymerisation.  
The nascent water soluble polymers were used to conjugate platinum, ferrocene and 
tetramethylmelamine derivative, respectively.  The percentage drug in each polymer drug 
conjugate was determined by considering the mass of the drug in the conjugate as a 
percentage of the total mass of the drug-polymer conjugate. 
  
Platinum was linked to the carrier via polymer attached amine, carboxyl and hydroxyl 
ligands.  Platinum content of the conjugates ranged from 7 to 11 % by mass.  The 
ferrocenylation agent, 4-ferrocenylbutanoic acid, and the tetramethylmelamine derivative,  
3-(4,6-bis(N,N-dimethylamino)-1,3,5-triazacyclohexatrien-2-yl) propanoic acid   was 
polymer-bound by amidation reactions.  Iron content of the ferrocence conjugated ranged 
from 2 to 12 % by mass. While the drug content based on tetramethylmelamine in the   
3-(4,6-bis[N,N-dimethylamino]-1,3,5-triazacyclohexatrien-2-yl) propanoic acid polymer 
conjugate ranged from 8.4 to 8.6 % by mass.  There was a preliminary attempt to co-
conjugate both, 4-ferrocenylbutanoic acid and 3-(4,6-bis[N,N-dimethylamino]-1,3,5-
triazacyclohexatrien-2-yl) propanoic acid to the same polymer.  This co-conjugate 
contained 2.9 % iron and 3.4 % tetramethylmelamine by mass. 
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CHAPTER 1 
INTRODUCTION 
 
Cancer still remains one of the most dreaded diseases of the twentieth century, 
although in existence since the earliest time this disease still instills fear in the hearts 
of many.  The disease is characterized by the uncontrollable cell division of cancerous 
cells, which progressively invade healthy tissue and ultimately kill the tissue and the 
host.1 
 
Although most common diseases may be effectively treated, e.g. tuberculosis through 
appropriate medication and effective health care, cancer still remains a grave concern 
since no effective treatment has yet been developed and the disease still affects a large 
portion of the worlds population  Furthermore epidemiological evidence suggests that 
this number is increasing because of the following reasons; 
1. increased urbanization resulting in environmental and dietary conditions 
encouraging the further spread of this disease.  
2. the spread of AIDS which comprises the immune system and makes an 
individual more susceptible to the development of cancerous lesions and 
virus-associated neoplasms.  
In South Africa the situation is as serious with cancer being the second highest cause of 
death in the white, colored and asian populations, and the third highest cause of death in 
the black population.1 
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Currently four approaches are used to treat cancer; 
I. Surgery  the surgical, physical removal of the damaged tissue 
II. Radiotherapy  the use of x-rays to destroy damaged tissue 
III. Immunotherapy  activation of the patients immune system, which then destroys 
the damaged tissue 
IV. Chemotherapy  the use of various chemical agents to destroy the damaged tissue 
 
Of these methods radiotherapy and chemotherapy remain the least invasive and the 
preferred alternative for widespread tissue damage.  In addition chemotherapy has shown 
special promise as a long-term adjuvant therapy following surgery or radiotherapy.  
There has therefore been a concerted effort to develop novel chemotherapeutic agents and 
increase the efficiency of more established agents.  
 
One approach to increase the efficiency of these more established agents has been to 
conjugate them to polymers, as an alternative drug delivery system.  This has stimulated a 
flurry of research throughout the world, including the Polymer laboratory at the 
University of the Witwatersrand.  This dissertation project represents a small contribution 
to this field. 
 
Aims of the study  
The objective of this project was to synthesize water-soluble macromolecular carriers, 
and subsequently conjugate them to platinum-based drug systems, a ferrocence derivative 
or a tetramethylmelamine derivative.  Selected conjugates were then submitted for 
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biomedical assessment and toxicological tests.  The background to this work will be 
discussed in Chapter 2 where the importance of water-soluble carriers will be 
emphasized.  Experimentally the following targets were defined; 
 
Target 1: Synthesis of water-soluble macromolecular carriers bearing amine, 
hydroxyl or carboxyl groups 
 
Target 2: Conjugation of macromolecular carriers to platinum, ferrocene or 
tetramethylmelamine to form carrier-drug conjugates 
 
Target 3: Submission of selected conjugates for biomedical and toxicological tests  
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
 
As the area of cancer chemotherapy, polymer drug conjugation and the various drug 
models used in this current project have been extensively studied internationally and the 
publication rate in this field remains prolific, I have restricted my survey to only a small, 
select number of review articles and original publications in writing this review. 
 
2.1. Introduction  
Cancer remains one of the primary causes of mortality both in South Africa and 
throughout the world1, consequently there has been an intensive research effort to 
develop various therapies.  Four types of therapies currently exist; 
I. Surgery  the surgical, physical removal of the damaged tissue 
II. Radiotherapy  the use of x-rays to destroy damaged tissue 
III. Immunotherapy  activation of the patients immune system, which destroy the 
damaged tissue.2 
IV. Chemotherapy  the use of various chemical agents to destroy the damaged  
tissue.3, 4, 5 
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Of these methods radiotherapy and chemotherapy remain the least invasive and the 
preferred alternative for widespread tissue damage.  In addition chemotherapy has shown 
special promise as a long-term adjuvant therapy following surgery or radiotherapy.  
There has therefore been a concerted effort to develop novel chemotherapeutic agents and 
increase the efficiency of more established agents. 
 
2.2. The Chemotherapeutic Treatment of Cancer 
 
The use of drugs to treat human disease is not a new concept and stretches far back as the 
ancient Egyptian civilisation.  However the modern era of chemotherapy began with the 
introduction of nitrogen mustard for the treatment of Hodgkins disease.  Subsequently 
steroids were used to treat prostate cancer and the antimetabolite, aminopterin caused the 
remission of acute leukaemia in children.6 
 
Presently there are numerous anti-tumour agents which are divided into various classes 
depending on their mode of action, these include; alkylating agents, antimetabolites and 
antibiotics.  Some of these may interact directly with tumour cells while others exist as 
prodrugs and must be activated, either in the tumour cell or in the liver to produce its 
desired effect.4, 5 
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Alkylating Agents 
Alkylating agents are a diverse family of compounds which share the following 
distinguishing characteristic; they have the ability to combine with cellular nucleophiles, 
primarily N- and O- nucleophilic groups on proteins and nucleic acids.  This feat permits 
them to impair DNA replication during mitosis.  A drug which functions thus is the 
alkylating agent nitrogen mustard; this drug contains a reactive ethylamine which binds 
to the N7 of the guanine molecule preventing the unwinding of the DNA double helix 
and its subsequent replication.  In clinical practice these drugs are used to treat acute and 
chronic leukaemia, myeloma, non-Hodgkins lymphoma and Hodgkins disease.7 
 
Antimetabolites 
Antimetabolites are synthetic analogues of essential naturally occurring substances 
required in the metabolism of normally proliferating cells.  These drugs achieve their 
effect by mimicking an important biological molecule and thus inhibiting an essential 
biological process, e.g. Methotrexate binds irreversibly to the enzyme dihydrofolate 
reductase, which stops the production of reduced folic acid thereby inhibiting thymidylate 
synthesis and the production of DNA which is necessary for cell replication.  
These drugs are used in the treatment of lymphoblastic leukaemia, Burkitts lymphoma 
and other lymphomas.7 
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Antibiotics 
These are naturally occurring anti-tumour agents and may be obtained from bacteria or 
plants. Their mode of action is numerous and includes; 
• bind to the enzyme topoisomerase II and stimulate strand breakage or sealing 
• poison the microtubule that forms during the process of mitosis 
• inhibiting RNA and thus blocking protein synthesis  
This class of anti-tumour agents is used in treating myeloid, acute lymphoblastic 
leukaemia, small cell lung cancer, ovarian cancer and a wide variety of heamatological 
malignancies.7 
 
2.3. The Polymer-Drug Delivery System 
However, all chemotherapeutic agents, both novel and established share the following 
deficiencies to various degrees; 
I. Poor water  solubility of the agent and thus poor bio-distribution.3, 4 
II. Poor specificity of the agent and thus increased toxicity.4 
III. Rapid excretion of the agent thus requiring continual administration.3,4 
 
A novel approach, which addresses all these problems and may be applied to both novel 
and established agents, recently gained momentum.8, 9, 10 This approach uses a drug 
delivery system to deliver the therapeutic agent to the site of action, offering the 
advantage that it increases the efficiency of all drugs (both established and novel drugs).  
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The rationale behind the drug delivery system is as follows:  It is well established that 
growing tumours establish their own blood supply.  This neovasculature is hyper-
permeable (leaky to macromolecules).  In addition to this enhanced permeability, tumour 
tissues also have an inadequate lymphatic system so that macromolecules are not 
efficiently drained from the tumours and remain trapped and concentrate in these tissues.  
An anti-tumour agent coupled to a suitable polymeric delivery system, therefore, has the 
potential of dramatically increasing the concentration of an anti-tumour agent within the 
tumour tissue.  Indeed this has been found, and in certain instances the concentration of 
polymer-drug conjugates in tumour cells have reached levels of 10-100 times higher than 
that of the free drug.  This phenomenon has been described as, enhanced permeability 
and retention  EPR effect).   
In addition, the systemic toxicity of the native drug was found to be dramatically reduced 
when conjugated to a carrier.11, 12 These extremely promising effects have resulted in a 
rigorous research effort to develop numerous drug delivery systems.  These included;  
1. Hydrogels  these are water-soluble cross-linked polymers in which the drug 
is physically entrapped.  These polymers then swell in water 
and release the drug at a regular rate.13, 14, 15 
2. Liposomes  a synthetic cellular membrane consisting of a hydrophobic core 
which contains the drug and a hydrophilic exterior which 
allows the drug to be carried in the circulation to the target 
tissue.16, 17  
3. Immuno-conjugates  The drug is covalently bound to an antibody which 
targets the drug to the affected tissue 
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4. Polymeric molecular conjugates  The drug is covalently bound to a synthetic 
polymer, which directs it to the target 
tissue.18, 19, 20 
These delivery systems were investigated because they were found to meet the following 
criteria to varying degrees; 
• Increased water solubility  
• Biocompatibility  
• Increased specificity  
• Selective release rate  
• Decreased excretion rate 
In this project it has been decided to concentrate specifically on synthetic water-soluble 
polymers as an appropriate drug delivery system.  This system has been chosen because 
of the following reasons; 
i. Synthetic polymers provide a controlled delivery system in which the polymer may 
be tailor-made to include a drug anchoring and a water soluble portion.  
ii. The water soluble portion may be regulated to ensure water solubility of the carrier, 
resulting in efficient delivery of the drug in the aqueous phase of the vasculature 
and the intraperitoneal cavity.  This smooth dissipation of the drug enhances 
bioavailability and reduces the risk of capture by the reticulo-endothelial system. 
iii. Biologically friendly polymers may be synthesized which result in a reduced 
immune response.  In addition polymer drug-conjugates have shown reduced 
toxicity compared to the free drug.  
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iv.  Polymer drug conjugates may be synthesized so that they stimulate the enhanced 
uptake of the drug via the endocytic process irrespective of the drug present.  In 
addition they may be tailor made so as to selectively target tumour cells e.g., the 
strongly cationic polymer may selectively be attracted to the negatively charged 
membrane present in some tumour cells. 
v. The molecular-mass of synthetic polymers may be tailored so as to maintain the 
correct balance to ensure entrapment inside tumour cells via the EPR effect and 
reduced excretion by the renal system.  In contrast, increased toxicity, as observed 
with a very high molecular-mass polymer will be impeded. 
vi. A polymer-drug carrier provides temporary protection against enzymatic attack, 
serum binding proteins and other depletion mechanisms to which the conjugate may 
be exposed, while being transported in the vasculature or the intraperitoneal cavity.  
This protection reduces, and in certain instances prevents, the premature release of 
the drug from the polymer. 
vii. The anchoring group within the polymer carrier may be effectively modified so that 
the polymer may carry more than one anti-tumour agent. 
 
2.4. Bioactive Agents  
Within the scope of this dissertation it has been decided to concentrate on three specific 
bioactive agents; these included the coordination compounds of the square-planar 
platinum (II) type, organoiron compounds of the ferrocene type and the drug, 
hexamethylmelamine 
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2.4.1.  Platinum Analogues 
While there are numerous metal containing anti-tumour drugs,21 only the platinum drugs 
have reached the level of routine clinical administration.  The primary drug in this family, 
cisplatin, was discovered accidentally by Rosenberg in the mid sixties.22, 23   Furthermore 
he found that although two forms of the complex exist, only the cis-isomer of this 
platinum complex was effective22, 23. 
 
The complex, cisplatin has been used extensively both as a single agent and in 
combination therapy against various tumours, including; cervical, ovarian, prostrate and 
testicular cancer.  Consequently the clinical performance and the mechanism of 
cytoxicity of this complex has been extensively studied and is the subject of numerous 
review articles.24, 25 
 
It is believed that cisplatin exerts its potent anti-tumour effect as follows; in the aqueous 
biological environment cisplatin is hydrolysed and forms both the monoaqua and diaqua 
derivative in which the chloro ligands are replaced by water molecules.  These complexes 
subsequently form a variety of hydroxyl species through deprotonation.  These modified 
complexes interact with various small and large molecules from phosphate groups to       
α-amino acids26 and RNA.  However the primary interaction occurs between the modified 
cisplatin complex and the N-7 portion of guanine and adenine.  This interaction results in 
the formation of intrastrand cross-links27 within the DNA helix, and the formation of 
DNA lesions which cannot be repaired by the tumour cell, resulting in its death. 
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Although cisplatin is efficient, it has numerous side effects e.g. nephrotoxicity and rapid 
excretion28 which must be prevented.  There has therefore been an intensive research 
effort to develop more efficient and less toxic drugs.  Recently these efforts have 
produced some promising analogues e.g. tetraplatin and cis-diaminetetrachloro 
platinum(IV).29  In addition novel second-generation platinum complexes containing 
carboxyl or hydroxyl ligands have also been developed, these complexes show special 
promise as they have reduced toxicity and are efficient against cisplatin-resistant tumour 
cell lines.  Fig. 1 illustrates cisplatin and other platinum analogues of clinical interest. 
 
Pt
NH2
Cl
Cl
NH2
cisplatin
Pt
NH2O
NH2
carboplatin
O
O
O
Pt
NH2Cl
tetraplatin
Cl
Cl
Cl NH2
Pt
NH2Cl
DACH-platinum
Cl NH2  
Fig. 1  Cisplatin and other platinum analogues 
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2.4.2.  Hexamethylmelamine (HMM) 
Hexamethylamine has been evaluated as an antineoplastic for more than twentyfive 
years, during which period this agent has shown limited activity against various tumour 
systems, Dunnings leukaemia, reticulum cell sarcoma and various murine sarcomas.  
Recently this agent has also shown special promise as a synergistic agent in combination 
with cisplatin and other platinum analogues.30 
Although the precise mechanism by which HMM exerts its effect is not known, the 
following mechanism has been suggested.31 Following administration the HMM is 
metabolically activated by cytochrome P450 to form a methylated HMM, carbinolamine 
and formaldehyde.  Methylated HMM and carbinolamine covalently interact with 
proteins while the other by-product, formaldehyde, interacts directly with DNA (fig. 2), 
thus preventing the cell replication of tumour cells and their unrestricted multiplication  
CH3
N
CH3
R
CH3
N
CH2OH
R
CH3
N
H
R
H H
ON
CH2R
CH3
O2, NADPH
Cyt P450
+
interact with macromolecules
(DNA and proteins)
+
interact with macromolecules 
(DNA and proteins)  
Fig. 2 Metabolism of HMM and its suggested mode of anitumour activity 
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2.4.3.  Ferrocene   
Ferrocene is a small, stable synthetic iron compound, which has numerous catalytic 
activity effects and a proposed anti-tumour activity.32, 33, 34, 35   Two mechanisms have 
been proposed to account for the anti-tumour effect of ferrocene.  The first involves an 
indirect mechanism whereby, ferrocene induces its anti-tumour effect by enhancing the 
immune response.  It achieves this by increasing the release of soluble factors, e.g. 
interferon γ, that are released from ferrocene-activated lymphocytes, which in turn 
stimulate peritoneal macrophages.36 
The second concept also involves an indirect mechanism whereby the oxidised form of 
ferrocene, ferrocenium, quenches a free radical species37, thus preventing the metastasis 
(recognized that free radicals are important carcinogens and their rapid neutralization 
provides a promising approach in terms of, the prevention of the development of tumor 
cells).  The mechanism whereby, ferrocene neutralizes a free radical occurs as follows; 
 
The ferricenium ion generated in a one-electron oxidation step from the neutral ferrocene 
complex reacts with the oxygen radical to form a dioxygen and ferrocene (fig. 3).  The 
ferricenium cation may also undergo free radical combination reactions by interaction 
with other free radical species.  The subsequent product undergoes re-arrangement from 
the metal substituted product to the ring substituted products, followed by deprotonation, 
which leads to an uncharged substituted ferrocene 
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Fe
R
H
FeR H
+
R
Fe
 
Fig. 3 Mode whereby ferrocenium ion neutralises free radicals 
 
This anti-tumour activity has prompted numerous investigations, the most promising 
being a comparative study in which various fericenium salts were evaluated for the 
antiproliferative effects against several human tumour clonongenic cell cultures.  The 
study showed that, although ferrocene (insoluble in water) showed no antiproliferative 
effects, the soluble ferricinium salts were found to be active.  Furthermore, a moderate 
activity was also identified for ferrocenylacetic acid.  These results were extremely 
promising in that they suggested;  
i. That ferrocene could be administered in its neutral form provided the ferrocene 
derivative had improved water solubility 
ii. That ferricinium salts, although effective, were not suitable for long term 
therapy as they were unstable at physiological pH 7.4 and would undergo 
reduction en route to the target tissue, thus nullifying their effect  
The observation that ferrocenylacetic acid was effective as an antiproliferative agent 
prompted a separate investigation in this laboratory in which the effect of the carboxyl 
side chain length on the reduction potential of the ferrocene-ferricinium couple was 
investigated.  It was found that the ferrocenylbutanoic acid gave the lowest positive 
reduction potential, thus offering optimal cation stability in biological environment.  
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Consequently ferrocenylbutanoic acid has been used primarily in this laboratory for the 
synthesis of ferrocene conjugates. Typically, the ferrocenylbutanoic acid is bound to the 
polymer chain via its carboxyl group to form an amide linkage (Fig. 4).  
 
 
NH
O
NH
O
R
NH
O
NH
O
x yR'
Fe = amide linkage
 
 
Fig. 4 General structure of an amide bound ferrocenyl butanoic acid to a water 
                 soluble carrier 
 
Preliminary biological results of polymer-bound ferrocenylbutanoic acid have shown 
excellent results against the human colon cancer cell line38 and thus have provided the 
impetus for the inclusion of this drug in the present dissertation.   
 
 
 
 
 
  
17
CHAPTER 3 
RESULTS AND DISCUSSION 
 
Considering the targets highlighted in chapter one, this dissertation project was carried 
out within the framework of the following work phases; 
Phase 1: Synthesis of water-soluble macromolecular carriers bearing amino, 
hydroxyl or carboxyl groups 
Phase 2: Conjugation of macromolecular carriers with selected antineoplastic drug 
models e.g. ferrocene, tetramethylmelamine or platinum type drugs to 
form carrier drug conjugates 
Phase 3: Submission of selected conjugates for biomedical and toxicological tests  
 
3.1 SYNTHESIS OF MACROMOLECULAR CARRIERS 
For the synthesis of the macromolecular carriers emphasis was placed on carriers which 
met the criteria highlighted in section 2.3.  Carriers which met these requirements were 
all of the polyamide-type and conformed to the following general structure, indicated 
below; 
SCONH
x
FCONH
y  
Fig. 5 Polyamide-type model 
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In this model, S stands for an extrachain- or intrachain-type group required to provide 
water solubility of the final conjugate, and F represents a functional group, inside or 
outside the main chain, capable of reversibly binding the drug species of choice.  Amine, 
dicarboxyl and dihydroxyl functional groups were used as alternative drug anchors.  
These various functional groups offered different advantages, e.g. the dihydroxyl and 
dicarboxyl functional groups held the drug by chelation and could be released rapidly by 
hydrolytic dissociation with immediate displacement of the drug by aqua ligands or other 
biological nucleophiles, while the amine functionality allowed for the formation of the 
amide linkage, requiring enzymatic cleavage and thus providing a slow release system.  
 
In this project fissionable groups were also directly incorporated directly into the main 
chain so as to allow for the regular release of the from the main chain. 
 
3.2. POLYASPARTAMIDES 
α, β-DL-Polyaspartamides were chosen as one of the primary water-soluble carriers to be 
used in this dissertation for the following reasons; 
i. α, β-DL-Polyaspartamides (PSI) may be conveniently synthesized from 
readily available starting material (DL-aspartic acid). 
ii. The molecular mass of the PSI on average ranges from 25000 to 35000 
which is well within the desirable range to prevent inherent polymer 
toxicity, but still large enough to prevent premature excretion by the renal 
system, thus facilitating increased drug circulation time. 
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iii. The structure of the copolyaspartamides may be reasonably controlled by 
regulating the feed ratio of the two nucleophiles participating in the ring 
opening reaction, thus controlling the ratio of the drug solubilizing to the 
drug anchoring component in the polymer chain. 
iv. The intrachain amide linkages provide for the gradual catabolism of the 
spent polymer chain, thus preventing excessive accumulation of the polymer 
in the body  
v.  The ability to increase the ratio of the hydrosolubilizing portion relative to 
the drug anchoring portion in a copolymer allows one to regulate the 
quantity of drug to be incorporated into the polymer chain 
vi. The introduction of tertiary amines as subunits into the polymer chain 
enhance both the solubility of the polymer and its affinity to target cells  
owing to increased pinocytic cell uptake.39 
Polyaspartamides are routinely prepared from poly-DL-succinimide by nucleophilic 
attack of the imide ring and its subsequent ring opening.  The ring opening is mediated by 
a mono-functional reagent, generally a mono-functional amine, under anhydrous 
conditions in a dipolar aprotic solvent at room temperature (Scheme 3.2a), in subsequent 
schemes only the alpha-peptide linkages will be illustrated for clarity.  The resulting 
polyaspartamides consist of both alpha and beta peptide linkages.  The poly-DL-
succinimide precursor was synthesized by the high temperature solution polymerization 
of DL-aspartic acid in orthophophosphoric acid according to the method described by 
Neri and Antoni.40  In this reaction the orthophosphoric acid serves as both the solvent 
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and the condensation agent.  The isolated crude polymer is treated with 
dicyclohexylcarbodiimide to facilitate further chain extension.  
O
O
N
n
Poly-D L-succinimide (PSI)                         beta peptide linkage 
H2N-R
anhydrous DMF, RT
NH
O
NHR
O
Poly-D L aspartamide
y
alpha peptide linkage
NH
O NHR
O
x
  
Scheme 3.2a: Synthesis of the copolymer, poly-α, β-DL-aspartamide 
 
As mentioned above, the polyaspartamides are prepared by the nucleophilic ring opening 
of the imide ring; numerous nucleophiles may be used independently or together to open 
the ring, and various polyaspartamides have been thus synthesized.  The 
polyaspartamides have therefore been divided into various classes depending on the type 
of side chain present on the polymer main chain; 
• homopolymer  consists of only one type of side chain within the polymer chain  
• copolymer  consists of two different types of side chain within the polymer chain  
•  terpolymer - consists of three different types of side chain within the polymer 
chain  
Within the structure of this dissertation work was focused specifically on the synthesis of 
several copolymers. These copolymers generally consisted of two distinct subunits which 
were randomly distributed in a fixed ratio in the polymer chain; 
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• R group which contained a hydroxyl or a tert-amino terminal group and 
represented the hydro-solubilizing (and in certain instances targeting) portion of 
the chain 
• R group which comprised a primary amino, hydroxyl or dicarboxyl terminal 
group and provided drug anchoring site on the chain 
The copolymers were prepared according to established procedures41, 42, 43, 44 developed 
in this laboratory, and involved the stepwise addition of two or more different amines in a 
given stochiometric feed ratio.  This resulted in a copolymer in which the subunits were 
randomly distributed along the polymer chain in a pre-determined ratio (scheme 3.2b).   
O
O
N
x+y
Poly-D, L-succinimide (PSI)                  
NH
O
NHR'
O
NH
O
NHR"
O
copolyaspartamide
1. 'R-NH2
2. "R-NH2
x y
 
Scheme 3.2b: Structure of the copolymer, poly-α,β-DL-aspartamide 
 
In this project synthetic efforts were focused specifically on two types of 
copolyaspartamide; 
• copolyaspartamide carriers in which the anchoring subunit remains constant but 
the hydrosolubilizing subunit varies between a hydroxyl terminal and a tertiary 
amino terminal group, in order to compare the effectiveness of the hydroxyl 
containing polymer with that of a tertiary amino containing polymer, in terms of  
drug targeting and solubility 
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• copolyaspartamide carriers in which the anchoring subunit varies between a 
hydroxyl, dicarboxylato or amino terminal group, in order to bind platinum, 
ferrocene and tetramethylmelamine, respectively.   
 
3.2.1. Copolyaspartamide carriers in which a hydroxyl is part of the solubilizing 
group  
 
Within this class of copolymers, the structure of two distinct types of copolymers was 
considered; 
• Hydroxyl-terminated water-soluble copolyaspartamides in which a primary amino 
group is present in the anchoring subunit of the polymer chain. The advantage of 
these polymers is that they provide an anchoring site for carboxyl containing 
drugs, e.g. ferrocenylbutanoic acid and the β-alanine-functionalized triazine 
compound. 
• Hydroxyl-terminated water-soluble copolyaspartamides in which a dicarboxyl 
group is present in the anchoring subunit of the polymer chain.  The advantage of 
these polymers is that they provide an anchoring site for the drug, DACH-Pt aq 
In each of these water-soluble copolymers the R group illustrated in scheme 3.2b above 
consisted of a 2-hydroxyethyl substituent and the reaction proceeded as illustrated in 
scheme 3.2.1a and 3.2.1b 
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O
O
N
x+y
             
NH
O
NH
OH
O
x
NH
O
NH
O
y
1. 
2. 
HO
NH2
anhydrous DMF
0-300C
RNH2
R
1a      R = expected     x:y = 9:1
found          x:y =9:1
1b     R =  expected     x:y = 9:1
found          x:y =9:1
NH2
O
O
NH2
 
Scheme 3.2.1a: Copolyaspartamides 1a, 1b 
O
O
N
x+y
NH
O
NH
OH
O
x
NH
O
NH
O
y
1. 
2. 
HO
NH2
anhydrous DMF
0-500C
RNH2
R
1c      R =  expected    x: y = 1:1
O
O
OH
OH   found        x: y = 1:1
1d       R =  OH
OH
expected    x: y = 9:1
 found        x: y = 9:1 
Scheme 3.2.1b: Copolyaspartamides 1c, 1d 
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The formation of the copolyaspartamides occurred in a two step process.  In the first step 
a given amount of ethanolamine (EA) was allowed to react with the PSI at room 
temperature for a period of 6-8 hrs.  Afterwards this solution was added drop-wise to the 
latter reagent 1,3-diaminopropane (PDA), ethylenedioxy-O,O-bis(2-ethylamine) 
(EDDA) or 3-amino-1.2-propanediol, present in a three fold excess.  It was found that 
this order of addition provided the correct balance to ensure complete ring opening of the 
remaining succinimide units, while preventing cross-linking of the polymer via the 
introduced amino terminal groups.  The reaction was conducted under strictly anhydrous 
conditions in order to prevent undesired hydrolytic ring opening of the succinimide units 
to form free carboxylic acid side groups.45 
 
For the dicarboxyl containing copolyaspartamides (scheme 3.2.1b) the reaction 
proceeded slightly differently.  In the first step a four fold excess of aspartic acid was 
allowed to react with the PSI over a period of 48 hrs at temperatures ranging from  
20-50 0C, to ensure that the aspartic acid reacted with at least 50 % of the succinimide 
units.  Afterwards, this suspension was added drop-wise to the required amount of EA 
needed to completely open the remaining succinimide ring, (in this instance it was found 
that a 10 % excess of EA was sufficient).  The reaction then proceeded for a further 8 hrs 
at room temperature, again, under strictly anhydrous conditions in order to prevent 
needless hydrolytic ring opening of the succinimide units.  
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The polymeric products were isolated as completely water-soluble solids following a 
series of steps which included filtering, precipitation with an organic non-solvent, 
extensive washing, aqueous dialysis (finally in tubing with a 25000 molecular-mass cut- 
off limit), and freeze-drying.  The polymers were obtained in yields ranging from 37 to 
57 %, with inherent viscosities ranging from 6 to 9 mL g-1 (table 3.2.1a).  Following 
isolation the polymers were characterized by 1H NMR spectroscopy (table 3.2.1b); 
analysis of the water-soluble copolyaspartamides yielded the following results; 
 
In most cases the 1H NMR spectra confirmed the structure of the polymer, this was 
indicated by the position of the various peaks in the spectra and the ratio in which they 
were found.  Furthermore integration of the various peaks in most cases produced a 
proton count which matched that predicted by the ideal structure.  However in certain 
instances there was a large discrepancy between the proton count predicted and that 
found, e.g. 1a.  In this instance the polymer was still deemed useful as the ratio of the 
solubilizing to anchoring group within the polymer was still acceptable.   
 
The experimental conditions and the analytical data are recorded in table 3.2.1a and b.  
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3.2.2. Copolyaspartamide carriers in which an amino side chain is part of the 
solubilizing group  
Within this class of copolymers, two distinct types of copolymers were synthesized; 
• Amine-terminated water-soluble copolyaspartamides in which a primary amino 
group is present in the anchoring subunit of the polymer chain.  
• Amine-terminated water-soluble copolyaspartamides in which a dicarboxyl or 
dihydroxyl group is present in the anchoring subunit of the polymer chain.  
 
In each of these water soluble copolymers mentioned above the R group illustrated in 
scheme 3.2b consisted of 3-(N, N-dimethylamino)propylamine (DMP).  This compound 
was favoured because it contained a tertiary amino group which is strongly basic and 
easily protonated under physiological conditions, thus producing a charged cationic 
terminal group which offer two advantages; 
• acting as a solubilizing agent, enhancing the solubility of the polymer  
• acting as a cell targeting agent, being preferentially attracted to tumour cells due 
to the very high negative charge present on the surface of selected tumour cells 
The DMP copolyaspartamides were synthesized according to scheme 3.2.2a and 3.2.2b.   
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O
O
N
x+y
             
NH
O
NH
O
N
x
NH
O
NH
O
y
1. 
2. 
anhydrous DMF
0-300C
RNH2
R
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1f      R =   x:y = 9:1
expected
found                 x:y = 3:1
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found                   x:y = 9:1
O
O
NH2
NH2
H2N N
 
Scheme 3.2.2a: Copolyaspartamides 1e, 1f 
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R NH2
 
Scheme 3.2.2b: Copolyaspartamides 1g, 1h 
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The synthetic approach followed was similar to that discussed in section 3.2.1 (hydroxyl- 
functionalized copolyaspartamide carriers).  It involved the two-step aminolytic ring 
opening of the PSI.  In the first step, DMP was allowed to react directly with the PSI for a 
period of 6hrs at room temperature.  In the second step this solution was added drop-wise 
to the required amount of PDA, EDDA, 3-amino-1,2-propandiol (in all these cases a three 
fold excess was required to ensure complete ring opening of the succinimide subunits and 
prevent cross linking).  Again the reaction proceeded in DMF under strictly anhydrous 
conditions.  
 
For the dicarboxyl-containing copolyaspartamides (scheme 3.2.2b) the reaction 
proceeded similarly to that described in scheme 3.2.1b.  In the first step a four fold 
excess of aspartic acid was reacted with the PSI over a period of 48 hrs at a temperature 
of 45 0C, to ensure that the aspartic acid reacted with at least 50 % of the succinimide 
units.  Afterwards this suspension was added drop-wise to the required amount of DMP 
needed to completely open the remaining imide rings (in this instance it was also found 
that a 10 % excess of DMP was sufficient).  The reaction then proceeded for a further  
8 hrs at room temperature under strictly anhydrous conditions. 
 
All the DMP-based copolyaspartamide polymers were isolated as described in Section 
3.2.1, in yields ranging from 41 to 61 %, and inherent viscosities ranging from 6 to  
8 mL g-1 (table 3.2.2a).  Following isolation the polymers were characterized by 1H NMR 
spectroscopy (table 3.2.2b), analysis of the water soluble DMP based copolyaspartamides 
yielded the following results; 
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In most cases the 1H NMR spectra confirmed the structure of the polymers, e.g. polymer 
1e contained a cluster of peaks in the region 4.7-1.5 ppm.  Within this cluster, peaks were 
found which were characteristic for DMP, PDA and the aspartamide polymer, 
respectively (Table 3.2.2a).  However in other instances the 1H NMR spectra did not 
match the predicted structure, e.g. 1g there was a slight a deficiency of DL-aspartic acid.  
This may be due to; 
• poor solubility of aspartic acid in the aprotic solvent resulting in a sluggish 
reaction 
• poor nucleophilic character of the nitrogen group of aspartic acid, thus facilitating 
poor addition of aspartic acid to the succinimide ring.  
 
The experimental conditions and the analytical data for these copolyaspartamides were 
recorded in table 3.2.2a and b  
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3.3 POLYAMIDOAMINES 
Polyaminodamines were chosen as the second source of water-soluble carriers to be used 
in this dissertation program.  These polymers were based on the Michéal-addition-
Ferruti-type synthesis of water-soluble carriers, in which a acidic vinyl group undergoes 
addition with a nucleophilic amino group under basic conditions.46, 47, 48, 49, 50 These 
polymers were chosen because they offer similar advantages to that of the 
copolyaspartamides, in addition they present a more controlled approach to introducing 
dicarboxyl terminal groups into the main chain and thus a more uniform polymer 
structure.  In this dissertation, work was concentrated on the polyamidoamines containing 
either the dicarboxyl or the dihydroxyl terminal group.  The reasons for choosing these 
functional groups were two fold; 
• The polyamidoamines provided a more controlled method of introducing the di-
carboxyl group into the polymer chain than was experienced with the 
dicarboxylated copolyaspartamides 
•
 The dicarboxyl- and dihydroxyl-terminated water-soluble carries have shown 
special promise within this laboratory as a carrier of 
diaminocyclohexanediaqáuplatinum(II) salt  (DACH-Pt aq), a drug system which 
has shown antiproliferative effectiveness against the human Hela carcinoma cell 
line.51 
The copolymers were prepared according to established procedures, which involved the 
stepwise addition of different amines in a given stoichiometric feed ratio to a double 
bond-activated biacrylamido compound.  This resulted in a copolymer in which the 
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subunits were uniformly distributed along the polymer chain in a pre-determined ratio 
(scheme 3.3).    
CONH R NHOC
R'-NH2
N
R'
CONHRNHOC
2. R''NH2 CONHRNHOC
N
R'
CONHRNHOC
N
di-vinyl monomer
polyamidoamine
CONHRNHOC
n
R"
 
Scheme 3.3: Structure of copolyamidoamines 
 
As mentioned above, we synthesized polyamidoamines, falling into two classes, the 
dihydroxyl-functionalized and the dicarboxyl-functionalized polymers.  The dicarboxyl- 
terminated polymer chain was characterized by the presence of R (scheme 3.3) 
containing a dicarboxyl-terminal group, while the dihydroxyl-terminated polymer chain 
was characterized by the presence of an R containing a dihydroxyl terminal group. 
 
3.3.1 Polyamidoamine carriers featuring dicarboxyl and hydroxyl functionalities 
In this group two synthetic approaches were followed to obtain the following carriers; 
• MBA based aspartic acid polymers 
• MBA based propanediol polymers  
• a bis-succinic acid derived polymer  
• a dihydroxyethylene(bisacrylamide) (DHEBA) derived polymer 
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3.3.1.1. Preparation of MBA-based DL-aspartic acid polymer and MBA-based APD 
polymer 
These carriers was synthesized according to the reaction scheme 3.3.1.1a, illustrated 
below 
 
 
CONH NHOC
(CH3)2CHOH
850C
CONH NHOC
inhibitor
H2O , 20-45
0
C, pH 9-10, 48hrs CONH NHOC
N
CONH NHOC
R
DMP, 450C, 24hrs, pH 9-10
ethanol amine, 200C, 6hrs
(added as a alkene qeunching
agent)
CONH NHOC
N
N
CONH NHOC
N
R
x y
Ii R = 
O
OH
O
OH
1j R = OH
OH
expected    x:y = 1:1
found         x:y = 1:1
expected    x:y = 1:1
found         x:y = 1:1
D,L-aspartic acid or 3-amino-1,2-propanediol 
 
Scheme 3.3.1.1: Copolyamidoamines 1i, 1j  
 
It involved the dissolution of recrystallized MBA, M1 (2:1) in water, and its reaction with 
the required amount of DL-aspartic acid or 3-amino-1,2-propanediol (APD).  The 
reaction proceeded under alkaline conditions for 48 hrs, at temperatures ranging from  
20-45 0C, to produce in-situ a disubstituted MBA-DL aspartic acid macro-monomer or a 
MBA-APD macro-monomer.  These macro-monomers were allowed to react with one 
mole equivalent of DMP at 45 0C for a further 24 hrs.  Any remaining vinyl groups were 
then neutralized by the addition of 5 % ethanolamine (mass:mass), and the reaction 
proceeded for a further 6hrs at 450C.  The polymeric product was isolated as a completely 
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water-soluble solid following a series of steps, which included filtering, precipitation with 
a organic non-solvent, extensive washing, aqueous dialysis (finally in tubing with a 
25000 molecular-mass cut-off limit), and freeze-drying.  The polymers were obtained in 
yields ranging from 18 to 22 %, with a inherent viscosity ranging from 11 to 12 mL g-1 
(table 3.3.1.1a).  Both the purified MBA- and the resulting MBA-based polymers were 
characterised by 1H NMR spectroscopy (table 3.3.1.1b and c) which confirmed both the 
structure of the monomer and the predicted polymers (table 3.3.1.1b and c) 
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3.3.1.2 Polyamidoamine carriers in which a 1,2-dihydroxyl functionality group is 
present within the polymer chain  
Preparation of DHEBA-Tria 
This carrier was synthesized according to the reaction scheme 3.3.1.2  
HO
NHCO
OH
OCNH
H2N O O
O NH2
Inhibitor
1. 10min, 50C, pH-9
2. 24hrs, 200C, pH-9
3. 48hrs, 450C, pH-9
3. EA, 6hrs, 20, pH-9
HO
NHCO
OH
OCNH
HN O
O
O NH
n
Purified DHEBA
HO
NHCO
OH
OCNH
inhibitor
IPA, 850C
M2
1k  
Scheme 3.3.1.2: Copolyamidoamine, 1k 
 
DHEBA purified by recrystallization was dissolved in water and to that was added Tria in 
a mol ratio of 1:1 (DHEBA:Tria).  The reaction proceeded for 72 hrs in alkaline medium 
at a temperature ranging from 20-45 0C.  Afterwards 5 % (mass:mass) EA was added to 
the solution and the reaction continued at RT, for a further 6 hrs.  This was to ensure that 
all remaining unreacted vinyl terminals present in the polymer were completely 
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inactivated.  The polymeric product was isolated as a completely water-soluble solid by 
the conventional series of steps.  The polymer was obtained in a yield of 22 %, with an 
inherent viscosity of 10 mL g-1 (table 3.3.1.2b).The recrystallized DHEBA, and the 
polymer was characterised by 1H NMR (table 3.3.1.2a) and both the monomer and the 
polymer agreed fairly well with the predicted structure.  For the DHEBA mononomer this 
was indicative of peaks at 5.4 ppm, (OCNH-CH(OH)-), 5.8 ppm, (OCNH-CH=CH2) 
and 6.2 ppm, (OCNH-CH=CH2).  Furthermore integration of these peaks produced the 
correct number of protons.  The polymer 1k consisted of appropriate Tria peaks.  
However it appeared that the DHEBA peak for OCNH-CH(OH)- had shifted into the 
region of 3.5 ppm, which was unusual and could not be accounted for.  
 
3.3.1.3.  Preparation of Diamido-succinic acid based  tria polymer 
This carrier was synthesized according to the reaction scheme 3.3.1.3a and 3.3.1.3b and 
involved two distinct steps.  
• synthesis of a bisacryloyl substituted macro-monomer, M3.  
• followed by the polycondensation of M3 with the diamine, Tria. 
The macro-monomer was synthesized as illustrated in scheme 3.3.1.3a 
NH2
OO
H2N
Cl
O
1. 2hrs, pH 7-7.5, 50C
2. 4hrs, RT, pH 7-7.5, RT
DI H20, NaOH
NH
OO
HN
OO
OH
NaCl
M3
OH OH OH
 
Scheme 3.3.1.3a: Synthesis of the diamidosuccinic acid precursor, M3 
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Two molar equivalents of acryloyl chloride were added drop-wise to an aqueous solution 
of diaminosuccinic acid, maintained at low temperature and slightly alkaline pH.  Both 
the low temperature and the narrow pH range were essential to ensure a successful 
reaction as; 
• the narrow pH range prevented the premature acid catalyzed hydrolysis of the 
acyl halide with formation of acrylic acid 
• the low temperature reduced the risk of free radical polymerization of the 
precursor with formation of a cross-linked polymer, which could occur as a result 
of excessive heat generated during this reaction 
Following the addition, the reaction proceeded for a further 4 hrs at 20 0C to ensure 
complete substitution of the amino groups, during which time the pH was regularly 
monitored and maintained at 6.5-8.0.  Afterwards the solution was acidified and the 
product was extracted using an appropriate organic solvent, and all traces of water were 
removed from the extract.  The pure product obtained by crystallization following 
reduction of the solvent volume, was isolated as a colourless solid, in a combined yield of 
74 % resulting from, collected (table .3.3.1.3a).  The crops were pooled and characterized 
by 1H NMR spectroscopy and agreed with the predicted structure (table3.3.1.3b). 
 
Following successful synthesis of the macro-monomer the copolymer was synthesized by 
the step growth addition polymerization of M3, and the diamine, 4,7,10-trioxa-1,13-
tridecanediamine (Tria),  according to the conditions described in scheme 3.3.1.3b 
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NHCO
OO
OH
OCNH
HO
H2N O O
O NH2
Inhibitor
1. 24hrs, RT, pH-9
2. 48hrs, 450C, pH-9
3. EA, 6hrs, RT, pH-9
NHCO
OO
OH
OCNH
HO
HN O
O
O NH
n
1l  
Scheme 3.3.1.3b:  Copolyamidoamine, 1l 
 
 
The polymer was prepared very similarly to the step-growth polymerization of MBA, 
Except that this reaction involved the immediate addition of the diamine (Tria) and M3.  
Afterwards the reaction proceeded for 96 hrs in an alkaline aqueous solution at 
temperatures ranging from 20 to 45 0C.  After this period any unreacted vinyl terminals 
were inactivated by the addition of 0.5 % (mass:mass) of EA, and the reaction continued 
for a further 6 hrs at 20 0C.  
The polymeric product was isolated as a completely water-soluble solid by the 
conventional work-up including aqueous dialysis (finally in tubing with a 25000 
molecular-mass cut off limit).  The polymer was obtained in a yield of 32 %, with an 
inherent viscosity of 14 mL g-1 (table 3.3.1.3c).  The structure of the polymer was 
characterised by 1H NMR (table 3.3.1.3d), giving the following results; 
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3.4. POLYAMIDES 
Polyamides were chosen as the third and final type of water-soluble carrier to be used in 
this dissertation program.  These polymers were prepared by the condensation 
polymerization process which occurs between a diamine and a diester (scheme 3.4).  
 
H2N R' NH2 RO R"
O
OR
O
NH R' NH
R"
O
O
n
polyamidediesterdiamine  
Scheme 3.4: General reaction for the formation of a polyamide 
 
These polymers were chosen because they offer the advantages provided by both the 
copolyaspartamides and the polyamidoamines.  These include; 
i. They may be conveniently synthesized from readily available starting material such 
as diethyl L-tartrate (Detart) and Tria 
ii. The molecular mass of the suitably fractionated polyamides on average ranges from 
25000 to 35000 provided the correct stochiometric ratio of reagents are added.  This 
molecular mass is well within the desirable range to prevent inherent polymer 
toxicity, but still large enough to prevent premature excretion by the renal system.  
iii. The structure of the polyamide is well defined  
iv. The intrachain amide linkages provide for the gradual catabolism of the spent 
polymer chain, thus preventing excessive accumulation of the polymer in the body.  
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v. This approach provides a controlled method of introducing the dicarboxyl or di-
hydroxyl functionalities into the polymer chain, thus providing a more uniform 
polymer.  
vi. The uniform distribution of dicarboxyl and dihydroxyl functionalities within the 
polymer chain also provides for a more efficient carrier system as it might enhance 
the drug binding capacity of the polymer for certain bioactive compounds 
 
Within this class of polymers work was focused specifically on two types; 
• the carboxyl-functionalized polyamide  
•  the hydroxyl-functionalized polyamide  
 The reason for this is that these functional groups selectively bind 
diaminocyclohexanediaqáuplatinum(II)salt  (DACH-Pt aq), a potent bioactive agent 
which has shown preliminary effectiveness against the Hela cell line, thus polymers with 
these functional groups would provide the ideal carrier for this potent drug.  
 
3.4.1 Polyamide carriers comprising a dihydroxyl functional group within the main 
chain 
Preparation of Poly(Detart-Tria)  
The polyamide Detart-Tria was prepared as described in scheme 3.4.1, equimolar 
quantities of diethyl L-tartrate (Detart) and of 4,7,10-trioxa-1,13-tridecanediamine (Tria) 
were allowed to react under mild polycondensation conditions in an alkaline organic 
medium for a period of two weeks, at temperatures ranging from 20-65 0C.  A yellow 
crystalline polymer was isolated by the conventional procedure as a solid in a yield of  
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42 % and an inherent viscosity of 12 ml g-1 (table 3.4.2a).  The polymer was 
characterised by 1H NMR, and the spectrum indicated the correct peaks in the required 
ratios (refer to table 3.4.2d) 
 
HO OH
OO
OO
H2N O O
O NH2
1. 24hrs, 200C, pH-9
2. 2 weeks, 20-600C, pH-9
HO
CO
OH
OC HN O
O
O NH
Na2CO3
DMSO
1m  
Scheme 3.4.1: Polyamide, 1m 
 
 
3.4.2 Polyamide carriers with a dicarboxyl functional group in the main chain 
Preparation of Poly(diethylmalonic- Tria) (DEM-Tria) 
The polyamide DEM-Tria was prepared as described in scheme 3.4.2a and 3.4.2b.  The 
synthetic approach was divided into two distinct steps; 
• synthesis of  2,2-bis(2-cyanoethyl)malonic acid M4 and the ester derivative, M5 
respectively (scheme 3.4.2a1 and 3.4.2a2) 
• polycondensation of M5 with Tria to produce a dicarboxyl functionalized, water- 
soluble, polyamide carrier (scheme 3.4.2b) 
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3.4.2a Synthesis of 2,2-bis(2-carbomethoxyethyl)malonic acid, M5 
In order to synthesize M5 it was necessary to prepare an appropriate precursor,  
2,2-bis(2-cyanoethyl)malonic acid, M4.  This precursor was readily synthesized by the 
Michéal Addition of acrylonitrile to the diethyl malonate (DEM), under slightly alkaline 
conditions.  The precursor was subsequently converted to a diester derivative by an 
anhydrous acid catalyzed conversion, in which the cyano groups were converted to ester 
groups.  It was necessary to perform this reaction under stringent anhydrous conditions as 
any trace of moisture resulted in destruction of the required precursor and the starting 
material.  This occurred because the acid-catalyzed hydrolysis was a competing reaction 
which would readily affect the cyano- and ester functional groups.  
 
 
CH3CH2O OCH2CH3
OO
1. NaOH, THF, 2hr, 200C
2. 
CN
, 24hrs, 5-200C
O
OH
O
OH
CNNC
M4  
Scheme 3.4.2a1: Formation of the 2,2-bis(2-cyanoethyl) malonic acid precursor, M4 
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O
OH
O
OH
CNNC
anhydrous HCl
CH3OH, 50C, 30min 
O
OH
O
OH
OO
O
O
M5  
Scheme 3.4.2a2: Conversion of M4 to the 2,2-bis(2-carbomethoxethyl) derivative, M5 
 
The 2,2-bis(2-cyanoethyl)malonic acid precursor was prepared by dissolving diethyl 
malonate (DEM) in tetrahydrofuran (THF).  To this solution was added 2.5 molar 
equivalents sodium hydroxide, and the mixture was stirred at 20 0C for 2 hrs.  This was to 
allow sufficient time for the base to dissolve, required to catalyze the Micheal Addition.  
Afterwards 2.5 mol equivalents of acrylonitrile were added drop wise to the mixture at  
0-5 0C, and the reaction was allowed to continue at 20 0C for a further 24 hrs.  The 
solution was alkalified to pH 9 and any unreacted DEM was extracted with ethyl acetate.  
The aqueous phase was acidified to pH 3-3.5 in order to convert the product from its salt 
to its free acid form, which was subsequently extracted with ethyl acetate.  The volume of 
the dried extract was reduced at room temperature under reduced pressure, and the 
product was allowed to crystallize.  The product, M4 was isolated as a colourless solid in 
a yield of 62 % and with a melting point of 145-147 0C (table 3.4.2a).  It was 
characterized by 1H NMR spectroscopy (table 3.4.2b), which produced a cluster of peaks 
in the region of 4.7-2.1.   
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Analysis of these peaks suggests the presence of M4, indicated by a peak at 2.7 ppm, 
CH2-CH2-C-(COOH)2 and a peak at 2.1 ppm, CN-CH2-C-CH2.  A third peak was also 
present due to the impurity acetone. 
 
Conversion of M4 to the diester analogue M5 was achieved by dissolving the precursor 
in anhydrous methanol at 0-5 0C and flushing it for 30 min at this temperature with 
anhydrous hydrogen chloride, produced by passing concentrated hydrochloric acid 
solution into 98 % (mass:mass) sulphuric acid.  The solvent volume was reduced under 
reduced pressure at a minimum temperature, to minimize hydrolysis.  The crude product 
was allowed to crystallize upon the addition of a non-solvent.  Re- crystallization 
afforded a colourless solid, with a total yield of 54 %, spread over three crops, melting at  
114-116 0C (table 3.4.2a), M5 was structurally characterized by 1H NMR which 
produced the required peaks at 3.7 ppm, CH2-COO-CH3, 2.7 ppm CH2-COO-CH3 and 
2.5 ppm, (HOOC)2C-CH2-CH2.  Furthermore integration of these peaks found them in 
the required ratio (table 3.4.2b).  
 
3.4.2b Polycondensation of M5 with Tria to produce a dicarboxyl, water soluble, 
polyamide carrier 
The water-soluble polyamide target compound was prepared under mild 
polycondensation conditions in which equimolar amounts of 4,7,10-trioxa-1,13-
tridecanediamine (Tria) and M5 were allowed to react in a alkaline organic medium for a 
period of two weeks at a temperature ranging from 20-65 0C (table 3.4.2c).  A yellow 
polymer was isolated by precipitation, extensive washing, dialysis and freeze-drying.  
The polymer was obtained in a yield of 32 %.  It was both water- and DMF-soluble and 
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had an inherent viscosity of 18 mL g-1.  The polymer was characterised by 1H NMR, 
which indicated the required peaks in the correct ratio except for the peaks at 3.4-3.0 ppm 
CONH-CH2-CH2 (COOH)2-CH2-CH2  which were slightly deficient (table 3.4.2d).  This 
may suggest a slight excess of Tria in the polymer which may be removed by more 
vigorous dialysis, risking hydrolysis of the polymer. 
H2N O O
O NH2
1. 24hrs, 200C, pH-9
2. 2 weeks, 20-600C, pH-9
O
O
O
Na2CO3
DMSO
CONHNHOC
O O
OHHO
OO
OH OH
O
O
O
O
M5
1n
n
 
Scheme 3.4.2b: Polyamide, 1n 
 
In summary, the polymers synthesized thus far, were all isolated as fully water soluble 
compounds and retained this property even after heating under vacuum for a period of  
48 hrs (suggested being equivalent to room temperature storage of the polymer for five 
weeks).  Consequently these polymers were deemed suitable for conjugation to bioactive 
agents.  
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As mentioned previously, the bioactive agents considered for coordination and 
conjugation respectively, included platinum complexes, ferrocene in the form of 
ferrocenylbutanoic acid, and tetramethylmelamine.  Fundamental coordination chemistry 
has been well established in this laboratory.  Coordination or conjugation involving these 
water-soluble carriers and the selected bioactive agents is of particular interest because of 
the following; 
• These water-soluble drug conjugates would contribute to the pool of existing 
conjugates which are required for biological testing 
• Some of the carriers used are novel and it would be interesting to compare their 
biological effect with those carriers of similar structure.  
• Some of the water-soluble carriers are especially noteworthy as they may be used 
to coordinate with the platinating agent DACH-Pt aq. 
• The novel bioactive agent, tetramethylmelamine, not before polymer-bound, will 
also be conjugated, and it would be interesting to compare the biological effect of 
the conjugated drug with the unbound agent. 
 
3.5. POLYMER PLATINUM COORDINATION 
Since the advent of cisplatin as a potent antitumour agent, there has been an extensive 
research effort to develop more efficient analogues.  This research impetus has resulted in 
the synthesis of platinum analogues in which the chloro ligands have been replaced with 
other suitable ligands, and in the preparation of novel trans-platinum complexes, and 
other 2nd and 3rd generation analogues with a high antitumour activity.  However, 
cisplatin still remains an essential component of any therapeutic regimen.  Consequently 
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numerous laboratories have attempted to reduce existing toxicity and resistance problems 
by conjugating this drug to water-soluble carriers, in this laboratory numerous methods 
have been developed to conjugate both cisplatin and the 2nd generation dicarboxylato-
complex to a tailor-made synthetic polymer.51, 52, 53 Within the scope of this dissertation 
platinum complexes have been prepared in which the metal is carrier bound via 
monoamine, dicarboxylato or dihydroxylato ligands.   
 
3.5.1.  Modes of polymer platinum anchoring 
In previous work in this laboratory numerous models for platinum chelation to the 
polymeric chain have been explored, depending on whether the polymer contains a 
terminal amino, dicarboxyl or dihydroxyl functional group.  These include; 
• The direct incorporation of the platinum complex into the main chain via diamine 
segments (model A) 
• The incorporation of platinum complexes into the polymer via pendent diamine 
functionality which forms part of the side chain of the polymer (model B) 
• The incorporation of platinum complexes into the polymer via pendent mono-
functionality which forms part of the side chain of the polymer  (model C) 
• The direct incorporation of the platinum complex into the main chain via pendant 
difunctional carboxyl or hydroxyl groups which forms part of the main chain  
(model D) 
• The incorporation of platinum complexes into the polymer via pendent difunctional 
hydroxyl or carboxyl groups which forms part of the side chain of the polymer 
(model E) 
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In models D and E, specifically for the hydroxyl functionalised polymers, coordination 
occurs via the oxy-group rather that than the hydroxyl group due to the presence of the 
platinum centre which make the hydroxyl group much more acidic, thus coordination 
occurs as R-O-----Pt rather than R-O(H)----Pt 
 
Specifically models C, D and E is described in this project, depending on the platinum 
complex investigated. For amine-containing platinum conjugates I concentrated 
specifically on model C, while for carboxyl-containing platinum conjugates polymer 
which corresponded to models D and E were used. 
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Models D' and E' apply both to dicarboxyl and dihydroxyl anchoring
functionalities  
Fig. 6  Models of platinum anchoring via the amino, dicarboxyl and 
dihydroxyl functionalities  
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3.5.2  Monoamine platinum complexes 
These platinum complexes are characterized by the presence of an amine ligand in the 
complex.  In this laboratory, four approaches have been used to conjugate amino group -
containing platinum complexes.  Of these approaches the most promising results have 
been found using model C.  These promising effects have provided the impetus in the 
present project to use various copolyaspartamides (refer to Scheme 3.4.2a) and 
coordinate it to platinum via an amine terminal functionality.  In the present work 
platination was performed in an aqueous medium at a ratio of 1:1,5 (polymer: potassium 
tetrachloroplatinate(II) at a pH range of 5 to 7, under meticulously controlled temperature 
and time conditions.  Purification by aqueous dialysis under controlled pH conditions 
resulted in removal of the unbound platinum salts.  This was followed by freeze drying 
which afforded the polymeric target products as water-soluble polymers in a yield 
ranging from 42 to 61 % and inherent viscosity from 8 to 11 mL g-1.  The platinum 
content was determined by atomic absorption, and ranged from 6 to 11 % (mass:mass).  
This was similar to previous results obtained in this laboratory.  In addition this 
percentage incorporation was much higher compared to that of DACH Pt aq and may be 
accounted for by the reduced steric hindrance experienced by platinum.  
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R1 = OH                     R2 = 
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DACH Pt
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x/y = 9:1
R2 = O O  
Scheme 3.5.2: Idealized structure of monoamine platinum(II) copolyaspartamide 
conjugates, of  structural type C; 1a-Pt, 1b-Pt, 1e-Pt, 1f-Pt (protonation effects 
ignored) 
 
3.5.3.   Polymer-Platinum Anchoring via the Dicarboxylato and the Dihydroxylato 
Ligands 
Second-generation platinum complexes anchored to carriers via the dihydroxyl and 
dicarbxyl ligands have yielded very promising results as mentioned before, showing 
superior activity against the Hela carcinoma cell line.  These promising findings have 
provided the drive for the synthesis of a variety of known and novel carriers for the 
dihydroxylato and dicarboxylato platinum complexes, so that established and new 
biological results could adequately be compared.  
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Models D and E were used to juxtapose the efficiency of the chain-integrated platinum 
complexation with that of the pendant platinum complexation system.  Previous results 
have suggested the pendant complexation produces a more efficient release of the drug as 
the pendant group is more prone to hydrolytic cleavage.  Although this argument is 
viable, it must be remembered that platinum complexes (especially those of the carboxyl 
and hydroxyl types), are particularly prone to pH changes, and thus more easily released.  
In this instance it may therefore be necessary to use a main chain-integrated complexation 
system in order to protect the complex from premature hydrolytic drug release. 
 
Carrier conjugation reactions with both the dicarboxylato- and dihydroxylato-platinum, to 
produce the conjugates, were performed using copolyaspartamides, copolyamidoamines 
and polyamides.  The process involved a two-step process in which the required amount 
of DACH Ptaq was pre-dissolved in an aqueous medium.  This solution added drop-wise 
to an aqueous polymer solution, in a mole ratio of 1.5:1 (DACH-Ptaq: polymer).  The 
reaction proceeded with stringent control of temperature, time and pH conditions.  After 
conventional work-up, both the dihydroxylato  and dicarboxylato-platinum conjugates 
were afforded as colourless solids.  The dihydroxylato platinum conjugates had yields 
ranging from 40 to 60 %  and inherent viscosities ranging from 7 to 13 mL g-1.  For the 
dicarboxylato-platinum conjugates, the yields ranged from 41 to 61 %, and the inherent 
viscosities from 9 to 15 mL g-1.  The platinum contents for both the dihydoxylato and 
dicarboxylato conjugates were determined by atomic absorption and ranged from 2 to  
9 % (mass:mass).  Comparison of the dicarboxylato conjugates with their dihydroxylato 
counter-parts for a given polymer indicated a consistently higher platinum content for the 
  
64
former.  This was due to the more stable co-ordination complex formed by the dicarboxyl 
functionality which was less prone to hydrolytic release. Furthermore, on average, the 
maximum quantity of platinum which could be incorporated was approximately 40 % 
which was lower than expected, but could be accounted for by the larger idealized 
structure of the platinum complex, resulting in increased steric effects.  Comparing the 
percentage DACH-Ptaq present in the various dicarboxyl-containing polymers suggest 
that in addition to the steric factor there appears to be additional factors inherent to the 
polymers which determine the quantity of platinum incorporated.  
NH
O
NH
O
R1
NH
O
NH
O
x y
NH
O
NH
O
R1
NH
O
NH
O
x y
HO
HO
R1 = OH
R1 = N
DACH Pt
 H2O, pH 5-6
1d-Pt x/y = 9:1
x/y = 9:11h-Pt
NH2H2N
Pt
O O
 
Scheme 3.5.3a: Idealized structure of dihydroxylato platinum(II) copolyaspartamide 
conjugates of structural type D, 1d-Pt, 1h-Pt (protonation effects ignored) 
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NH2H2N
Pt
OH
OH
O
O
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Scheme 3.5.3b: Idealized structure of dicarboxylato platinum(II) copolyaspartamide 
conjugates, of  structural type E, 1c-Pt, 1g-Pt (protonation effects ignored) 
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O
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Scheme 3.5.3c: Idealized structure of dihydroxylato platinum(II) polyamide conjugates, of 
structural type D, 1m-Pt (protonation effects ignored) 
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Scheme 3.5.3d: Idealized structure of dicarboxylato platinum(II)polyamides conjugates, of  
structural type D, 1n Pt (protonation effects ignored) 
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1. DACH Ptaq
2. 24hrs, RT, pH-9
3. 48hrs, 450C, pH-9
4. EA, 6hrs, RT, pH-9
O
NHCO
O
OCNH
HN O
O
O NH
n
HO
NHCO
OH
OCNH
HN O
O
O NH
n
Pt
NH2H2N
1l-Pt
 
Scheme 3.5.3e: Idealized structure of dihydroxylato platinum(II) tria-based 
polyamidoamine conjugates, of structural type D, 1l-Pt (protonation effects ignored) 
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4. EA, 6hrs, RT, pH-9
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O
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Scheme 3.5.3f: Idealized structure of dicarboxylato platinum(II) tria-based 
polyamidoamine conjugates, of structural type D, 1k-Pt (protonation effects ignored) 
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Scheme 3.5.3g: Idealized structure of dihydroxylato platinum(II) MBA-based 
copolyamidoamine conjugates, 1j-Pt (protonation effects ignored) 
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Scheme 3.5.3.h: Idealized structure dicarboxylato platinum(II) MBA-based 
copolyamidoamine conjugates, of structural type D, 1i-Pt (protonation effects 
ignored) 
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3.6. POLYMER FERROCENE CONJUGATION 
It has been well established that metallocene compounds exhibit interesting biological 
and biomedical effects, the most interesting being the anti-proliferative effect of 
ferrocene, mediated by its ability to neutralize free radical species which are recognized 
as important protagonists of cancer.  This interesting property of ferrocene complexes has 
resulted in an intensive research initiative within this lab aimed at optimizing the 
conjugation of ferrocene compounds to appropriate polymers and evaluating their 
biological activity.  
 
Consequently ferrocene has been chosen as one of the other drugs within this project.  
The approach followed involved the ferrocenylation of polyaspartamides using the 
ferrocene derivative, ferrocenylbutanoic acid, M6.  The derivative was synthesised using 
an established laboratory procedure, and subsequently conjugated via amidation of the 
carriers.  This linkage was felt appropriate as it was reasonably stable and would 
withstand premature hydrolytic release of the drug.  
 
Ferrocene derivatisation was achieved through an established literature procedure, 
involving Friedel Crafts acylation of ferrocene and Clemensen reduction of the keto 
intermediary to ferrocenylbutanoic acid, described in scheme 3.6a.  TLC performed in 
petroleum ether:acetone (1:1) signified completion of the reaction.  The acid was afforded 
as a yellow solid in 40 % yield with a melting point of 118-120 0C.  Polymer ferrocene 
anchoring proceeded as described in scheme 3.6b.  It involved the dissolution of the 
polymer in a aprotic solvent and its subsequent conjugation to the ferrocenylbutanoic acid 
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in a ratio of 1: 1.2, using an appropriate coupling agent (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU)).  The reaction proceeded under 
anhydrous conditions for a period of 2-2.5 hrs at room temperature.  The polymer 
ferrocene conjugate was isolated following a series of purification steps which included 
precipitation in a non-solvent, scrupulous washing, aqueous dialysis and freeze-drying.  
The product was obtained as a brownish, water soluble crystalline material, with  
various yields and inherent viscosities depending on the polymer used for binding.  The 
iron content in the conjugate was determined using AA spectroscopy and ranged from  
2  to 12 % (mass:mass). 
Fe O
O
O
AlCl3
CH2Cl2
COOH
O
Fe
Zn/Hg
amalgam
HCl
COOH
Fe
 
Scheme 3.6a: Preparation of ferrocenylbutanoic acid, M6 
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Scheme 3.6b: Ferrocenylation of copolyaspartamide carriers, 1a, 1b, 1d and 1e 
(protonation effects ignored) 
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3.7. POLYMER CONJUGATION OF β-ALANINE-MODFIED 
TETRAMETHYLMELAMINE DERIVATIVE 
A tetramethylmelamine derivative was chosen as the third medicinal agent to be included 
within this dissertation.  The reasons for this were as follows; 
i. It is a well established anti-tumour agent, whose efficiency has 
been illustrated against a broad range of tumours 
ii. Its poor water solubility makes it a ideal agent which may be used 
to illustrate the benefits of a drug carrier system to provide 
efficient distribution in central circulation 
iii. It may be synthesized using conventional methods and relatively 
inexpensive starting material. 
 
However the structure of hexamethylmelamine does not lend itself to effective 
conjugation to the polymer carrier.  To achieve suitable conjugation the following 
approach was followed; 
• synthesis of the tetramethylmelamine surrogate.   
• conjugation of the surrogate to the carrier 
 
3.7.1 Synthesis of the tetramethylmelamine derivative 
The tetramethylmelamine derivative, M8, was synthesized from cyanuric chloride 
according to scheme 3.7.1, to produce an aromatic intermediate, M7, which reacts further 
to afford the tetramethylmelamine precursor, M8.  The intermediate M7 was prepared by   
a literature procedure, which involved the drop-wise addition of two equivalents of 
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dimethylamine in a slightly alkaline dioxane: water solution, at 0-5 0C for 30 min.  The 
reaction proceeded for 48 hrs at RT during which the alkalinity (pH 7-7.5) was 
maintained by the regular addition of sodium hydroxide.  This was to neutralize the 
hydrochloric acid which formed as a by-product during this reaction. The product, M7, 
was isolated, following alkalification, extraction with an organic solvent and 
recrystallisation in ethyl acetate.  The product was isolated as a white crystalline solid, in 
yields of 74 % and with a melting point of 115-117 0C.  The product was further 
characterized by 1H NMR.  The tetramethylmelamine derivative, M8, was prepared by 
refluxing M7 with 2.5 times equivalent β-alanine in dioxane: water, under slightly 
alkaline conditions, for a period of 48hrs.  Afterwards the product M8 was isolated as a 
white crystalline material following extraction and recrystallization from water.  The 
product was obtained in a yield of 42 % and characterized by 1H NMR spectrum (200 or 
400 Mhz), measured in D2O at slightly acidic pH (table. 3.7.1b) 
 
The 1H NMR indicated only a single peak for M7 in the region of 3.0 ppm and failed to 
conclusively confirm, if this was the required compound.  Melting point of M7 matched 
that present in literature and on this basis the compound was deemed appropriate to carry 
forward.  Analysis of M8 indicated a cluster of peaks in the region of 3.7-2.4, identified 
as follows; 3.7-3.5 ppm, CH2-CH2-COOH, 3.1-3.0 ppm, 2.5-2.4 ppm NH-CH2-CH2, 
which match those protons present in M8. 
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N N
N ClCl
Cl
N(CH3)2, NaOH
H2O:dioxane, 
1. 1/2hr, 0-50C
N N
N(CH3)2N N(CH3)2
Cl
M7
H2N OH
O
 NaOH ,dioxane
reflux
48hrs
N N
N N(CH3)2(CH3)2N
NH OH
OM8
2. 48hrs/RT 
 
Scheme 3.7.1: Synthesis of the tetramethylmelamine derivative, M8 
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3.7.2 Conjugation of the precursor, M8, to a copolyaspartamide carrier 
Polymer-triazine anchoring proceeded as described in scheme 3.7.2, It involved 
dissolution of M8 in a aqueous solvent followed by pH adjustment to a slightly alkaline 
pH (6.5-7.5) and stirring for 30min. Afterwards M8 was isolated by freeze-drying and 
conjugated to a polyaspartamide as follows; 
 
The polymer was dissolved in an aprotic solvent and subsequently conjugated to M8 in a 
ratio of 1:2.0 (polymer:M8), using a appropriate coupling agent (2-(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)).  The reaction proceeded 
under anhydrous conditions, in the dark for a period of 2-2.5 hrs at room temperature, and 
slightly alkaline pH (7-8.5).  The polymer triazine conjugate was isolated following a 
series of purification steps which included precipitation in a non-solvent, scrupulous 
washing, aqueous dialysis and freeze-drying under varying pH conditions.  The product 
was obtained as a colourless, water soluble crystalline material, with various yields  
(47-61 %) and inherent viscosities (7-9 mL g-1) depending on the polymer used for 
conjugation.  The quantity of tetramethylmelamine present was determined by 1H NMR, 
using the methyl protons as a reference (table 3.7.2b), and were in the range of  
8.4-8.6 %, considering the mass of the drug as a percentage of the total mass of the drug-
polymer conjugate.  This was similar to that obtained for the ferrocene conjugates, which 
is expected considering a similar conjugation method was used.  A future approach may 
involve conjugating the derivative under acidic conditions using a alternative conjugating 
agent. 
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Scheme 3.7.2: Conjugation of M7 to copolyaspartamide carriers, 1e*, 1f 
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CHAPTER 4 
EXPERIMENTAL 
4.1 GENERAL PROCEDURES 
Melting points were determined in sealed capillary tubes.  1H NMR spectra was recorded 
on a 200 or 400 MHz instrument, in either D2O or CDCl3 solutions.  Chemical shifts, δ in 
ppm, were recorded relative to the internal standard sodium 3-(trimethylsilyl)-2,2,3,3-d4-
propionate and tetramethylsilane, respectively.  The pD of selected samples were adjusted 
to  10, with NaOH.  All spectra have an intergration error limit of 10-15 %. 
 
Inherent viscosities (ηinh) were determined in a Cannon-Fenske viscometer tube at a 
temperature of 37 ± 0.5 0C, in deionized water (c = 2 g/100 ml), and the results were 
given as mL g-1.  Dialyses was performed using cellulose membranes (Spectrum 
Industries Inc., Los Angeles, USA) of the type Spectra/Por 4 (12,000  14,000 molecular-
mass cut off limit) and Spectr/Por 6 (25,000 molecular mass cut off limit).  Dialysis was 
performed over various periods and pH conditions against large volumes of distilled 
water.  
 
A Virtis Bench Top 3 freeze drier (-40 0C, 10-15 Pa) was used to freeze-dry all the 
polymer samples (both carrier and conjugate samples).  The samples were further dried 
for 2 days at 60-65 0C, under reduced pressure in an Abderhalden apparatus, with CaCl2 
as the drying agent.  Iron and platinum content of the conjugates were determined by 
Anglo American Laboratories, Crown Mines, Johannesburg. 
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4.2 REAGENTS AND SOLVENTS 
Deionized water was used for dialysis and viscometric operations, including any 
preparative work.  Methanol and THF were distilled in a faint stream of nitrogen, prior to 
use.  Dimethylformamide (DMF) was distilled under reduced pressure in a faint stream of 
nitrogen, with a fore-run of 15 % being discarded, once distilled the DMF was further 
dried over molecular sieves 4 Ǻ.  The aprotic solvent DMSO was also dried over 
molecular sieves 4 Ǻ. 
 
The following reagents (Fluka AG and/or Aldrich GmbH) were used as received: 
acryloyl chloride, 3-amino-1,2-propanediol (APD), DL-aspartic acid, 
orthophosphoric acid (85 %), diethyl malonate (DEM),  
N,N-dicyclohexylcarbodiimide (DCC), N,N-(1,2-
dihydroxyethylene)bisacrylamide (DHEBA), 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), ferrocene, ethanolamine (EA), 
3-(dimethylamino)propylamine (DMP), 1,3-diaminopropane (PDA), Diethyl L-
tartrate (Detart), ethylenedioxy-O,O-bis(2-ethylamine) (EDDA), diethyl ether, 
cyanuric chloride, 4,7,10-trioxa-1,13-tridecanediamine (Tria), triethylamine 
(NEt3) 
 
Potassium tetrachloroplatinate (K2PtCl4) was donated by the Western Platinum 
Refinery. 
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A technical grade mixture of isopropanol and propanol (propylol) was used in 
certain recrystallization and precipitation procedures.   
N,N-methylenebisacrylamide and (1,2-dihydroxyethylene)bisacrylamide were 
recrystallized from isopropanol in the presence of the inhibitor hydroquinone  
(0.5 % by mass).  Throughout this dissertation the amount of polymeric material is 
given as base moles. 
 
4.3 PREPARATION OF MACROMOLECULAR CARRIERS 
4.3.1 Poly(DL-succinimide) 1 
Polysuccinimde was prepared according to the literature method of Neri and Antoni.40 
This involved the high-temperature solution polymerisation of DL-aspartic acid in 
orthophosphoric acid and its subsequent treatment with dicyclohexylcabodiimide at a 
reduced temperature.  The product of three successive runs were pooled together to 
produce a polymer with an average inherent viscosity (DMF) of 30 mL g-1. 
 
4.3.2 Poly α,β-DL- aspartamides from polysuccinimide 1 by aminolytic ring 
opening 
 
Copolyaspartamide 1a 
Poly-α,β-DL-[N-(2-hydroxyethyl)aspartamide (90)-co-N-(3-aminopropyl)aspartamide (10)]  
0.97 g (10 mmol) of 1 was dissolved in 20 ml DMF and flushed with nitrogen.  To this 
solution was added 0.543g (9 mmol) EA drop wise, under nitrogen.  The reaction 
proceeded for 8 hrs at RT.  This solution was added drop wise to 0.222 g (3 mmol) PDA 
in 5 ml DMF, under nitrogen at 0-5 0C.  The solution was stirred at this temperature for a 
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further 16 hrs, and for 24 hrs at RT.  The volume of DMF was reduced to 10 ml and the 
polymer was precipitated with 15 ml ether: hexane (2:1) (volume:volume).  The 
precipitate was washed copiously with cold acetone and re-dissolved in 20 ml water.  The 
polymer solution was dialysed successively for 48 hrs in Spectra/Por 4 tubing and 48 hrs 
in Spectra/Por 6 tubing.  The retentate was freeze-dried, and a beige coloured solid was 
obtained, which was post-dried for 2 days at 60-65 0C, under reduced pressure in an 
Abderhalden apparatus.  This gave copolyaspartamide 1a, with a yield of 0.553 g (57 %);  
ηinh(H2O) 9 mL g-1 
 1H NMR, δ/ppm: 3.7-3.5 ppm CH2-CH2-OH (18H)18H, 3.4-3.0 ppm CONH-
CH2-CH2OH and CONH-CH2CH2 (20H)18H, 2.8-2.5 ppm Asp CH2 and  
 -CH2-NH2 (22H)24H, 1.6-1,4 ppm CH2CH2CH2 (18H)18H 
 
Copolyaspartamide 1b 
Poly-α,β-DL-[N-(2-hydroxyethyl)aspartamide-co-N-(3,6-dioxa-9-azanonyl)aspartamide] 
Copolyaspartamide1b was prepared analogous to that of 1a.  Except that in this instance 
444 mg (3 mmol) ethylenedioxy-O,O-bis(2-ethylamine) (EDDA) in 10 ml DMF was 
used instead of PDA.  Following analogues precipitation, dialysis, and drying conditions 
produced copolyaspartamide 1b, with a yield of 0.475 g (49%); ηinh(H2O) 8 mL g-1 
1H NMR, δ/ppm:4.7-4.5 ppm Asp CH 10H(10H), 4.0-3.5 ppm CH2-CH2-OH and 
CH2CH2-O 26H(26H), 3.5-3.0 ppm CONH-CH2- 20H(20H),  
3.0-2.5 ppm Asp CH2 and -CH2-NH2 21(22) 
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Copolyaspartamide 1c 
10 mmol of 1 was dissolved in 20 ml DMF, under nitrogen.  To this solution was added 
10 mmol DL-aspartic and 10 mmol triethylamine.  A white suspension formed which was 
stirred at 45 0C for 48 hrs.  The suspension was cooled to 0-5 0C and to it was added 
0.336 g (5.5 mmol) EA.  The reaction continued for a further 8 hrs at RT.  The 
suspension was filtered and the volume of the filtrate was reduced to 10 ml.  The polymer 
was precipitated with 25 ml Et2O:hexane (2:1) and the precipitate was washed copiously 
with cold acetone and re-dissolved in 30 ml distilled water.  The polymer solution was 
dialysed successively for 48 hrs in Spectra/Por 4 tubing and 48 hrs in Spectra/Por 6 
tubing.  The retentate was freeze-dried and a white solid was obtained, which was post 
dried for 2 days at 60-65 0C, under reduced pressure in an Abderhalden apparatus.  This 
gave copolyaspartamide 1c, with a yield of 0.359 g (37 %); ηinh(H2O) 6 mL g-1 
 1H NMR, δ/ppm: 4.7-4.5ppm Asp CH 1H(3H), 4.0-3.5ppm CH2-CH2-OH 
2H(2H),  3.5-3.0ppm CONH-CH2 2H(2H), 3.0-2.5ppm Asp CH2 3H(6H) 
 
Copolyaspartamide 1d 
Poly-α,β-DL-[-(2-hydroxyethyl)aspartamide-co-N-(2,3-dihydroxypropyl)aspartamide] 
Copolyaspartamide 1d was prepared similar to that of 1a,  except that in this instance 
0.273 g (3 mmol) 3-amino-1,2-propanediol (APD) dissolved in 10 ml DMF, was used 
instead of PDA.  Following analogous precipitation, dialysis, and drying operations, this 
produced copolyaspartamide 1d, with a yield of 0.514 g (53 %); ηinh(H2O) 8 mL g-1 
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 1H NMR, δ/ppm: 4.0-3.5 ppm CH2-CH(OH)-CH2OH, CH(OH)-CH2OH and 
CH2-CH2-OH 21H(21H), 3.5-3.0 ppm CONH-CH2- 19H(20H), 3.0-2.5 ppm, 
 Asp CH2 21H(20H) 
 
Copolyaspartamide 1e 
Poly-α,β-DL-[N-(3-dimethyamino)propyl-aspartamide-co-N-(3-
aminopropyl)aspartamide] 
0.97 g (10 mmol) of 1 was dissolved in 20 ml DMF and flushed with nitrogen.  To this 
solution was added 0.767 g (7.5 mmol) DMP dropwise, under nitrogen.  The reaction 
proceeded for 6 hrs at RT.  This solution was added drop wise to 0.556 g (7.5 mmol) 
PDA, under nitrogen at 0-5 0C.  The solution was stirred at this temperature for a further 
16 hrs, and for 24 hrs at RT.  The volume of DMF was reduced to 12 ml and the polymer 
was precipitated with 25 ml Et2O:hexane (2:1).  The precipitate was washed copiously 
with cold acetone and re-dissolved in 30 ml water.  The polymer solution was dialysed 
successively for 48 hrs in Spectra/Por 4 tubing and 48 hrs in Spectra/Por 6 tubing.  The 
retentate was freeze-dried, and a beige coloured solid was obtained, which was post-dried 
for 2 days at 60-65 0C, under reduced pressure in an Abderhalden apparatus.  This gave 
copolyaspartamide 1e, with a yield of 0.592 g (61 %); ηinh(H2O) 7 mL g-1 
 1H NMR, δ/ppm: 3.5-3.0ppm CONH-CH2-CH2 8H(8H), 3.0-2.5ppm Asp-CH2 
9H(8H), 2.4-2.2ppm  -CH2-N 8H(8H), 2.2-2.0ppm N-CH3 17H(18H), 1.7-
1,5ppm, CH2CH2CH2 8H(8H) 
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Copolyaspartamide 1f 
Poly-α,β-DL-[N-(3-dimethyamino)propyl-aspartamide-co-N-(3,6-dioxa-9-
azanonyl)aspartamide] 
Copolyaspartamide 1f was prepared similar to that of 1e.  Except that in this instance  
3 mmol ethylenedioxy-O,O-bis(2-ethylamine) (EDDA), was used instead of PDA.  
Following analogous precipitation, dialysis, and drying conditions, produced 
copolyaspartamide 1f, with a yield of 0.650 g (67 %); ηinh(H2O) 8 mL g-1 
 1H NMR, δ/ppm: 3.7-3.5 ppm CH-2CH2-O 7H(6H), 3.4-3.45 ppm  
 CONH-CH2-CH2-O 2H(2H), 3.45-3.2 ppm CONH-CH2 18H(20H),  
 3.2-2.6 ppm Asp-CH2,  2.5-2.3 ppm CH2-CH2-N 18H(20H),2.3-2.1 ppm  N-
CH3 53H(54H) 1.7-1,5 ppm , CH2CH2CH2 (2H)2H 
 
Copolyaspartamide 1g 
Copolyaspartamide 1g was prepared similar to that of 1c.  Except that in this instance  
5 mmol DMP was used rather than EA.  Following analogous precipitation, dialysis, and 
drying operations, this produced copolyaspartamide 1g, 0.398 g (41 %);  
ηinh(H2O) 6 mL g-1 
 1H NMR, δ/ppm: 4.5-4.0 ppm Asp CH 2H(3H), 3.0-2.55 ppm CONH-CH2- 
2H(2H), 2.55-2.45 ppm Asp CH2 4H(6H), 2.45-1.8 ppm CH2-CH2-N 3H(2H), 
and N-CH3 6H(6H), 1.6 -1.4 ppm CH2-CH2-CH2 2H(2H) 
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Copolyaspartamide 1h 
Poly-α,β-DL-[N-(3-dimethyamino)propyl-aspartamide-co-N-(2,3-
dihydroxylpropyl)aspartamide] 
10 mmol of 1 was dissolved in 20 ml DMF and flushed with nitrogen.  To this solution 
was added 0.920 g (9 mmol) DMP drop wise, under nitrogen.  The reaction proceeded for 
8 hrs at RT.  This solution was added drop wise to 0.273 g (3 mmol) APD in 15 ml DMF, 
under nitrogen at 0-5 0C.  The solution was stirred at this temperature for a further 16 hrs, 
and for 24 hrs at RT.  The volume of DMF was reduced to 10 ml and the polymer was 
precipitated with 20 ml ether:hexane (2:1) (volume:volume).  The precipitate was washed 
copiously with cold acetone and re-dissolved in 20 ml water.  The polymer solution was 
dialysed successively for 48 hrs in Spectra/Por 4 tubing and 48 hrs in Spectra/Por 6 
tubing.  The retentate was freeze-dried, and a beige coloured solid was obtained, which 
was post dried for 2 days at 60-65 0C, under reduced pressure in an Abderhalden 
apparatus.  This gave copolyaspartamide 1h, with a yield of 0.495 g (51 %); ηinh(H2O) 7 
mL g-1 
 1H NMR, δ/ppm: 4.0-3.5 ppm CH2-CH(OH)-CH2OH and CH(OH)-CH2OH 
3H(3H), 3.5-3.0 ppm CONH-CH2- 20H(20H), 3.0-2-5 ppm Asp CH2 
20H(20H), 2.5-2.0 ppm CH2-CH2-N 19H(18H) and N-CH3 54H(54H),  
 1.7 ppm-1.5 ppm CH2-CH2-CH2 18H(18H) 
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4.3.3 Copolyamidoamines 
Recrystallization of MBA, M1 
7.7085 g (50 mmol) of MBA was dissolved in boiling 30 ml isopopanol, with 0.5 % 
(mass:mass) hydroquinone, and the solute was allowed to crystallise at RT .  Three crops 
were collected 5.40 g (35 mmol) and characterised by 1H NMR 
1H NMR, δ/ppm: 6.3-6.1 ppm OCNH-CH=CH2 4H(4H), 5.9-5.7 ppm OCNH-
CH=CH2 2H(2H), 4.7-4.6 ppm OCNH-CH2-CONH 2H(2H) 
 
Recrystallization of DHEBA, M2 
2.002 g (10 mmol) of MBA was dissolved in boiling 20 ml isopropanol, with 0.5 % 
(mass:mass) hydroquinone and the solution was allowed to crystallise at RT with the 
addition of 5ml hexane .  Two crops were collected 1.72 g (8.5 mmol) and characterised 
by 1H NMR 
1H NMR, δ/ppm: 6.4-6.1 ppm OCNH-CH=CH2 4H(4H), 5.8-5.7 ppm OCNH-CH=CH2 
2H(2H), 5.5-5.3 ppm OCNH-CH(OH)-CH(OH) 2H(2H)  
 
Copolyamidoamine 1i 
1.542  g (10 mmol) recrystallized MBA, M1, was dissolved in 10 ml warm water.  To 
this solution was added (0.667 g) 5 mmol Asp and 0.530 g (5 mmol) Na2CO3, and the pH 
was adjusted to 9.  The solution was stirred in the dark for 24 hrs at RT and a further 24 
hrs at 45 0C.  Afterwards 0.510 g (5 mmol) DMP was added to the solution and the 
reaction continued at RT for 24hrs.  During the last 6hrs of this period 0.5 % EA 
(mass:mass) was added to the solution, to neutralise any unreacted vinyl groups.  The 
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volume of the polymer solution was reduced to form a viscous oil, which was copiously 
washed with propylol.  The oil was dissolved in 30ml water and pH of the solution was 
reduced to 5.0.  The solution was then dialysed successively for 48hrs in Spectra/Por 4 
tubing and 48 hrs in Spectra/Por 6 tubing.  The retentate was freeze-dried and a white 
solid was obtained, which was post dried for 2 days at 60-65 0C, under reduced pressure 
in an Abderhalden apparatus.  This gave copolyamidoamine, 1i, with a yield of 0.278 g 
(18 %); ηinh(H2O) 11 mL g-1 
 1H NMR δ/ppm: 4.6-4.3 ppm CONH-CH2-NHCO 3H(4H), 2.7-2.5 ppm 
CONH-CH2CH2 8H(8H), 2.4-2.1 ppm N-CH2-CH2 and CHCH2CO 
14H(12H), 2.0-1.8ppm N-CH3 6H(6H), 1.6-1,4 ppm CH2CH2CH2 2H(2H) 
 
Copolyamidoamine 1j 
Copolyamidoamine 1j was prepared similar to that of 1i, except that in this instance 
(0.456 g) 5 mmol 3-amino-1,2-propandiol dissolved in 5 ml de-ionised water was used 
rather than aspartic acid.  In addition, only 0.212 g (2 mmol) Na2CO3 was used instead of 
5 mmol.  Following analogous precipitation, dialysis, and drying operations, this 
produced copolyamidoamine 1j, with a yield of 0.339 g (22 %); ηinh(H2O) 12 mL g-1 
 1H NMR, δ/ppm: 4.6-4.3 ppm CONH-CH2-NHCO 4H(4H), 3.8-3.6 ppm 
CH(OH)-CH2-OH 1H(1H), 3.6-3.4 ppm CH2CH(OH)CH2 2H(2H),  
 2.8-2.6 ppm CONH-CH2CH2 7H(8H), 2.6-2.4 ppm N-CH2-CH2 and N-CH2-
CH(OH) 13H(12H), 2.4-2.2 ppm N-CH3 7H(6H) 1.8-1,6 ppm CH2CH2CH2 
2H(2H) 
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Copolyamidoamine 1k 
1.001 g (5 mmol) recrystallised DHEBA, M2, was dissolved in 20 ml warm water.  To 
this solution was added 0.212 g (2 mmol) Na2CO3 and 1.102 g (5 mmol) Tria drop wise 
and the reaction continued for 24 hrs at RT and a further 24 hrs at 45 0C.  Throughout this 
period the flask was light protected and the pH of the solution was maintained at 9.  
Afterwards 0.5 % EA (mass:mass) was added to the solution, to neutralise any unreacted 
vinyl groups, and the reaction was continued in the dark for a further 6 hrs.  The volume 
of the polymer solution was then reduced to form a viscous oil, which was copiously 
washed with propylol.  The oil was dissolved in 25 ml water and pH of the solution was 
reduced to 8.0.  The solution was then dialysed successively for 48 hrs in Spectra/Por 4 
tubing and 48 hrs in Spectra/Por 6 tubing.  The retentate was freeze-dried and a brownish 
solid was obtained, which was post-dried for 2 days at 60-65 0C, under reduced pressure 
in an Abderhalden apparatus.  This gave copolyamidoamine, 1k, with a yield of 0.220 g 
(22 %); ηinh(H2O) 10 mL g-1 
 1H NMR, δ/ppm: 3.5-3.0 ppm CH2-CH2-O and CONH-CH(OH)-CH 
14H(14H),  2.7-2.5 ppm CONH-CH2CH2 4H(4H), 2.5-2.3 ppm HN-CH2-CH2 
4H(4H),  2.4-2.2 ppm N-CH3 7H(6H) 1.6-1,4 ppm CH2CH2CH2 4H(4H) 
 
Macromonomer, M3 
0.407 g (4.5 mmol) of acryloyl chloride were added drop wise to an aqueous solution of 
0.297 g (2 mmol) diaminosuccinic acid, maintained at 0-5 0C and slightly alkaline pH, 
6.5-8.5.  Following the addition, the reaction proceeded for a further 4hrs at 20 0C to 
ensure complete substitution of the amino groups, during which time the pH was 
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regularly monitored and maintained at 6.5-8.5.  Afterwards the solution was acidified to 
pH 3.0 and the product was extracted with five times 20 ml portions of ethyl acetate, and 
all traces of water were removed from the extract. The pure product obtained by 
crystallization following reduction of the solvent volume, was isolated as a colourless 
solid, in a combined yield of 0.302 g.  The crops were pooled and characterized by  
1H NMR spectroscopy  
 1H NMR, δ/ppm: 6.3-6.1 ppm H2C=CH-CONH 4H(4H), 5.8-5.6 ppm 
CH2=CH-CONH 2H(2H), 4.7-4.5 ppm,  OC-CH-CONH 2H(2H) 
 
Copolyamidoamine 1l 
Copolyamidoamine 1l was prepared similar to that of 1k.  Except that in this instance 
2.562 g (10 mmol) M4 was used instead of DHEBA, also 1.272 g (12 mmol) Na2CO3 
was used instead of 2 mmol.  Following analogous precipitation, dialysis (except that the 
polymer solution was adjusted to pH 5 prior to dialysis), and drying operations, this 
produced copolyamidoamine 1l, with a yield of 0.820 g (32 %); ηinh(H2O) 14mL g-1 
 1H NMR, δ/ppm: 4.5-4.3 ppm CONH-CH-CO 1H(2H), 3.7-3.5 ppm CH2-CH2-
O 12H(12H), 2.7-2.5 ppm CONH-CH2-CH2 4H(4H), 2.4-2.1 ppm NH-CH2-
CH2 1H(4H), 1.8-1,6ppm CH2CH2CH2 4H(4H) 
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4.3.4 Ester-amine polycondensation derived polyamides 
Polyamide 1m 
A mixture of 1.310 g (5 mmol) Detart 1.102 g (5 mmol) Tria, and anhydrous Na2CO3 
(0.5 g) was saturated with nitrogen and stirred at RT for 24 hrs.  The mixture was then 
diluted with 6 ml DMSO, resaturated with nitrogen and stirring continued for 13 day at 
450C.  Subsequently the polymer mixture was copiously washed with propylol to produce 
a viscous mixture.  The viscous mixture dissolved in 15 ml water, and the pH of the 
polymer solution was adjusted to 6.0.  The solution was dialysed successively for 24 hrs 
in Spectra/Por 4 tubing and 48 hrs in Spectra/Por 6 tubing.  The retentate was freeze-
dried and a yellowish solid was obtained, which was post-dried for 2 days at 60-65 0C, 
under reduced pressure in an Abderhalden apparatus.  This gave polyamide, 1m,  
with a yield of 0.498 g (38 %); ηinh(H2O) 12 mL g-1 
 
 1H NMR, δ/ppm: 4.5-4.3ppm CONH-CH(OH) 2H(2H), 3.7-3.5ppm CH2-CH2-
O 13H(12H), 3.4-3.2ppm CONH-CH2-CH2 4H(4H), 2.8-2.6ppm NH-CH2-
CH2 1H(2H) 1.8-1,6ppm CH2CH2CH2 4H(4H) 
 
Macromonomer M4 
A mixture of 11 mmol NaOH and 50 ml THF was stirred for 2 hrs at RT.  To this mixture 
was added 0.801 g (5 mmol) of diethyl malonate (DEM) at 0-5 0C, and the mixture was 
stirred for a further 4hrs at RT.  Acrylonitrile (AcCN), 0.811 g (15 mmol) was added drop 
wise to this mixture at 0-5 0C and the reaction continued for a further 24 hrs at RT.  
Afterwards the THF was removed under reduced pressure, and a colourless solid was 
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collected.  The solid was dissolved in 20 ml water and to it was added three times 20 ml 
portions of ethyl acetate, to remove any unreacted DEM.  The aqueous solution was 
collected and acidified with HCl to pH 3.  To this aqueous solution was added five times 
20 ml portions of ethyl acetate, and the ethyl acetate was collected.  All traces of moisture 
were removed from the organic phase by the addition of 5 g of anhydrous MgSO4.  The 
volume of the ethyl acetate, was reduced to 15 ml under reduced pressure, and hexane 
was added until turbidity, the product was allowed to crystallize at 0-5 0C.  This gave a 
colourless solid, with a yield of 0.545 g and a melting point of 145-147 0C  
 1H NMR, δ/ppm: 2.8-2.6 ppm CH2-CH2-C-(COOH)2 2H(2H), 2.2-2.0 ppm  
 CN-CH2-CH2 2H(2H) 
 
Macromonomer M5 
M5, 1.051 g (5 mmol) was dissolved in anhydrous methanol at 0-5 0C and flushed for 
30min at this temperature with anhydrous hydrogen chloride, produced by passing 
concentrated hydrochloric acid solution into a stream of 98 % (mass:mass) sulphuric acid.  
The solvent volume was reduced under reduced pressure at 20 0C to minimize hydrolytic 
depolymerisation.  The crude product was allowed to crystallize upon the addition of 
hexane.  Re-crystallization afforded a colourless solid, with a total yield of 0.568 g, 
spread over three crops, melting at 114-116 0C 
 1H NMR, δ/ppm: 3.8-3.6 ppm CH3-OCO 5H(6H), 2.8-2.6 ppm CH2-CH2-C-
(COOH)2 2H(2H), CN-CH2-CH2 2H(2H) 
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Polyamide 1n 
Polyamide 1n was synthesized similarly to that described for 1m, except in this instance, 
macro-monomer M5 was used instead of Detart.  In addition 1.060g (10mmol) Na2CO3 
and 5 % (mass:mass) 2-hydroxypyridine was added to the reaction mixture.  After 
analogous isolation and purification, a colourless solid with a yield of 0.420 g (40 %),  
ηinh(H2O) 14mL g-1, was obtained 
 1H NMR, δ/ppm:  3.7-3.5 ppm CH2-CH2-O 12H(12H), 3.4-3.0 ppm CONH-
CH2-CH2 3H(6H), 2.6-2.4 ppm NH-CH2-CH2 1H(2H), 2.2-1.7 ppm 
(COOH)2-CH2-CH2 3H(4H), 1.7-1,5 ppm CH2CH2CH2 4H(4H) 
 
4.4 POLYMER CONJUGATION 
4.4.1a Polymer-platinum conjugation 
Monoamineplatinum(II)--copolyaspartamide conjugates  
1a-Pt 
Compound 1a, 300 mg (0.190 mmol) was dissolved in 10 ml distilled water, the solution 
was saturated with nitrogen and to it was added 79 mg (0.228 mmol) K2PtCl4.  The 
mixture was stirred in the dark at room temperature for 24 hrs and for a further 48 hrs at 
45 0C, also in the dark.  During this period the pH was maintained at 5-7, and in the last 
30 min the pH was adjusted to 4.0 by the addition of HCl.  At this point 0.5 g of NaCl 
was added and the solution was stirred at room temperature for a further 2 hrs.  The 
brownish solution was dialysed in Spectra/Por 4 tubing for 48 hrs against water kept at 
pH 4-5.  Freeze drying of the retentate afforded a water-soluble solid in the yield of  
165 mg (55 %), ηinh(H2O) 11 mL g-1.  Analysis found: Pt, 8.2 % (10.3 %) 
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1b-Pt  
Compound 1b, 300 mg was dissolved in 15 ml distilled water, the solution was saturated 
with nitrogen and to it was added 91 mg (0.218 mmol) K2PtCl4, whereupon the pH 
dropped to 4.0.  The pH was adjusted to 5-7 by the addition of Na2CO3.  The mixture was 
stirred in the dark at room temperature for 24 hrs and for a further 48 hrs at 45 0C, also in 
the dark.  During this period the pH was maintained, and in the last 30 min the pH was 
adjusted to 4.0 by the addition of HCl.  At this point 0.5 g of NaCl was added and the 
solution was stirred at room temperature for a further 2 hrs.  The reddish  brown solution 
was dialysed in Spectra/Por 4 tubing for 48 hrs against water kept at pH 4-5.  Freeze 
drying of the retentate afforded a water soluble solid in the yield of 141 mg (47 %), 
ηinh(H2O) 9 mL g-1.  Analysis found: Pt, 7.0 % (10 %) 
 
1e-Pt 
This conjugate was prepared very similarly to that described for 1a-Pt, in this instance 
however 300 mg (0.391 mmol) of 1e carrier and 206 mg (0.4692 mol) K2PtCl4 was used.  
Analogous purification and isolation procedures, afforded a brown solid in the yield of  
183 mg (61 %), ηinh(H2O) 9 mL g-1.  Analysis found: Pt, 9 % (16 %) 
 
1f-Pt 
Compound 1f, 300 mg (0.147 mmol) was dissolved in 12 ml distilled water, the solution 
was saturated with nitrogen and to it was added 74 mg(0.177 mmol) K2PtCl4, whereupon 
the pH dropped to 4.0, the pH was adjusted to 5-7 by the addition of Na2CO3.  The 
mixture was stirred in the dark at room temperature for 24 hrs and for a further 48 hrs at 
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45 0C, also in the dark.  During this period the pH was maintained, and in the last 30 min 
the pH was adjusted to 4.0 by the addition of HCl.  At this point 0.5 g of NaCl was added 
and the solution was stirred at room temperature for a further 2 hrs.  The reddish brown 
solution was dialysed in Spectra/Por 4 tubing for 48hrs against water kept at pH 4-5.  
Freeze drying of the retentate afforded a water soluble solid in the yield of 126 mg  
(42 %), ηinh(H2O) 7 mL g-1.  Analysis found: Pt, 7.5 % (8.4 %) 
 
Dihydroxylato platinum(II) polyaspartamide conjugates 
1d-Pt 
Compound 1d, 300 mg (0.188 mmol) was dissolved in 10ml distilled water.  To this was 
added 112 mg (0.282 mmol) DACH-Pt aq. and pH of the solution adjusted from 4.0 to 
6.0-7.0 with Na2CO3.  The reaction proceeded in the dark for 24 hrs and then at 45 0C for 
48hrs, throughout this period the pH was maintained with either nitric acid or Na2CO3.  
Afterwards the reddish brown was dialysed in Spectra/Por 4 tubing for 48 hrs against 
water kept at pH 5-6.  Freeze drying of the retentate afforded a water soluble brown solid 
in the yield of 111 mg (37 %), ηinh (H2O) 7 mL g-1.  Analysis found: Pt, 2.09 % (9.8 %) 
 
1h-Pt 
Compound 1d, 300 mg (0.151 mmol) of 1h was dissolved in 10 ml distilled water.  To 
this was added 90 mg (0.227 mmol) DACH-Pt aq. and pH of the solution was 6-7.0.  The 
solution was stirred in the dark for 24 hrs and then at 45 0C for 48 hrs, throughout this 
period the pH of 6-7.0 was maintained with either nitric acid or Na2CO3.  Afterwards the 
reddish brown solution was dialysed in Spectra/Por 4 tubing for 48 hrs against water kept 
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at pH 5-6.  Freeze drying of the retentate afforded a water soluble brown solid in the yield 
of 162 mg (54 %), ηinh(H2O) 9mL g-1.  Analysis found: Pt, 7.69 % (8.2 %) 
 
Dicarboxylatoplatinum(II) copolyaspartamide conjugates 
1c-Pt 
This conjugate was prepared very similarly to that described for 1d-Pt, in this instance, 
however 300 mg (0.781 mmol) of 1c carrier and 465 mg (1.17 mmol) DACH Ptaq was 
used.  Analogous purification and isolation procedure, afforded a brown solid in the yield 
of 123 mg (41 %), ηinh(H2O) 7 m Lg-1.  Analysis found: Pt, 5.93 % (25 %) 
 
1g-Pt 
This conjugate was prepared very similarly to that described for 1g-Pt, in this instance 
however 300 mg (0.702 mmol) of 1c carrier and 418 mg (0.1.053 mol) DACH Ptaq was 
used.  Analogues purification and isolation procedure, afforded a brown solid in the yield 
of 129 mg (43 %), ηinh(H2O) 8mL g-1.  Analysis found: Pt, 9.02 % (23 %) 
 
4.4.1b  Polyamidoamine-Pt conjugates 
Dihydroxylatoplatinum(II) polyamidoamine conjugates 
1j-Pt 
Compound 1j, 300 mg (0.599 mmol) was dissolved in 10 ml distilled water.  To this was 
added .357 mg (0.899 mmol) DACH Ptaq. and pH of the solution adjusted from 4.0 to 
6.0-7.0 with Na2CO3.  The reaction proceeded in the dark for 24 hrs and then at 45 0C for 
48 hrs, throughout this period the pH was maintained with either nitric acid or Na2CO3.  
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Afterwards the reddish brown was dialysed in Spectra/Por 4 tubing for 48 hrs against 
water kept at pH 5-6.  Freeze drying of the retentate afforded a water soluble brown solid 
solid in the yield of 126 mg (42 %), ηinh(H2O) 9 mL g-1.  Analysis found:  
Pt, 4.37 % (22 %) 
 
1k-Pt 
Compound 1k, 300 mg (0.717 mmol) was dissolved in 10 ml distilled water.  To this was 
added 427 mg (1.075 mmol) DACH-Pt aq. and pH of the solution was 6-7.0.  The 
solution was stirred in the dark for 24 hrs and then at 45 0C for 48 hrs, throughout this 
period the pH of 6-7.0 was maintained with either nitric acid or Na2CO3.  Afterwards the 
reddish brown solution was dialysed in Spectra/Por 4 tubing for 48 hrs against water kept 
at pH 5-6.  Freeze drying of the retentate afforded a water soluble brown solid solid in the 
yield of 121 mg (47 %), ηinh(H2O) 9 mL g-1.  Analysis found: Pt, 2.15 % (24 %) 
 
Dicarboxylatoplatinum(II) copolyaspartamide conjugates 
1i-Pt 
This conjugate was prepared very similarly to that described for 1d-Pt, in this instance 
however 300 mg (0.553 mmol) and 330 mg (0.830 mmol) DACH-Pt aq was used.  
Analogous pH regulation throughout the reaction 6-7, purification and isolation 
procedure, afforded a brown solid in the yield of 171 mg (57 %), ηinh(H2O) 7 mL g-1.   
Analysis found: Pt, 4.59 % (21 %) 
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1l-Pt 
This conjugate was prepared very similarly to that described for 1g-Pt, in this instance 
however 300 mg (0.630 mmol) of 1l and 375 mg (0.945 mmol) DACH-Pt aq was used.  
Analogous pH regulation throughout the reaction 6-7, purification and isolation 
procedure, afforded a brown solid in the yield of 177 mg (59 %), ηinh(H2O) 8 mL g-1.  
Analysis found: Pt, 6.53 % (22 %) 
 
4.1c Polyamide-Pt conjugates 
Dihydroxylatoplatinum(II) polyamide conjugates 
1m-Pt 
Compound 1m, 300 mg (0.859 mmol) was dissolved in 10 ml distilled water.  To this 
was added 1.289 mmol DACH-Pt aq. and the pH of the solution adjusted from 5.0 to 6.0-
7.0 with Na2CO3.  The reaction proceeded in the dark for 24 hrs and then at 45 0C for  
48 hrs, throughout this period the pH was maintained with either nitric acid or Na2CO3.  
Afterwards the reddish brown solution was dialysed in Spectra/Por 4 tubing for 48 hrs 
against water kept at pH 5-6.  Freeze drying of the retentate afforded a water soluble 
brown solid solid in the yield of 168 mg (56 %), ηinh(H2O) 9 mL g-1.  Analysis found:  
Pt, 2.95 % (26 %) 
 
Dicarboxylatoplatinum(II) polyamide conjugates 
1n-Pt 
This conjugate was prepared very similarly to that described for 1m-Pt, in this instance 
however 300 mg (0.672 mmol) of 1n and 400 mg (1.008 mmol) of DACH Ptaq was used.  
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Analogous pH maintenance throughout the reaction (pH 6-7), purification and isolation, 
afforded a brown solid in the yield of 183 mg (61 %), ηinh(H2O) 11 mL g-1.  Analysis 
found: Pt, 7.31 % (23 %) 
 
4.4.2 Polymer-ferrocene conjugation 
Preparation of 4-ferrocenylbutanoic acid, M6 
Ferrocene derivation was achieved through an established literature procedure, involving 
Fiedel Crafts acylation of ferrocene and Clemensen reduction of the keto intermediary to 
ferrocenylbutanoic acid, TLC performed in petroleum ether:acetone (1:1) signified 
completion of the reaction.  The acid was afforded as a yellow solid, in 0.840 g (40 %) 
yield with a melting point of 118-120 0C. 
1H NMR, δ/ppm:  4.3-4.1 ppm ferrocenyl 8H(9H), 2.4-2.2 ppm CH2-CH2-
CH2 4H(4H), CH2-CH2-CH2 2H(2H) 
 
Copolyaspartamide-Fc conjugates 
1a-Fc 
Compound 1a, 300 mg (0.190 mmol) was dissolved in 3 ml DMF and the solution was 
saturated with nitrogen.  To this solution was added 62 mg (0.228 mmol) 
ferrocenylbutanoic acid and 83 mg (0.209 mmol) of the coupling agent (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)).  The 
reaction proceeded under anhydrous conditions in the dark for a period of 2-2.5 hrs at 
room temperature, pH of 8-9.  The polymer-ferrocene conjugate was precipitated with 10 
ml Et2O:hexane (2:1), and re-dissolved in 10ml water with 0.5 % ascorbic acid.  The 
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solution was dialysed in Spectra/Por 4 tubing for 1 hr against water kept at pH 5-6, and 
subsequently for 24 hrs against de-ionised water, pH 6-7.  Freeze-drying of the retentate 
afforded a water soluble brown solid in the yield of 174 mg (58 %), ηinh(H2O) 9 mL g-1.  
Analysis found: %Fe, 2.61 % (3.0 %) 
 
1b-Fc 
Polymer 1b, 300 mg (0.182 mmol) was dissolved in 3 ml DMF and the solution was 
saturated with nitrogen.  To this solution was added 59 mg (0.218 mmol) 
ferrocenylbutanoic acid and 80 mg (0.200 mmol) of the coupling agent (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)).  The 
reaction proceeded under anhydrous conditions in the dark for a period of 2-2.5hrs at 
room temperature, pH of 8-9.  The polymer ferrocene conjugate was precipitated with 10 
ml Et2O:hexane (2:1), and re-dissolved in 10 ml water with 0.5 % ascorbic acid.  The 
solution was dialysed in Spectra/Por 4 tubing for 1hr against water kept at pH 5-6, and 
subsequently for 24hrs against water, pH 6-7.  Freeze-drying of the retentate afforded a 
water soluble, brown solid in the yield of 201 mg (67 %), ηinh(H2O) 8 mL g-1.  Analysis 
found: % Fe 2.5 % (2.9 %) 
 
1e-Fc 
Polymer 1e, 300 mg (0.391 mmol) was dissolved in 3 ml DMF and the solution was 
saturated with nitrogen.  To this solution was added 128 mg (0.469 mmol) 
ferrocenylbutanoic acid and 171 mg (0..4301 mmol) of the coupling agent (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)).  The 
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reaction proceeded under anhydrous conditions, in the dark for a period of 2-2.5 hrs at 
room temperature, pH of 8-9.  The polymer ferrocene conjugate was precipitated with 
10ml Et2O:hexane (2:1), and re-dissolved in 10 ml water with 0.5 % ascorbic acid.  The 
solution was dialysed in Spectra/Por 4 tubing for 1hr against water kept at pH 5-6, and 
subsequently for 24 hrs against DI water, pH 6-7.  Freeze-drying of the retentate afforded 
a water soluble, brown solid in the yield of 201 mg (67 %), ηinh(H2O) 8 mL g-1.  Analysis 
found:  %Fe 5.0% (5.5%) 
 
1f-Fc 
Polymer 1f, 300 mg (0.147 mmol) was dissolved in 3 ml DMF and the solution was 
saturated with nitrogen.  To this solution was added 48 mg (0.176 mmol) 
ferrocenylbutanoic acid and 77 mg (0.194 mmol) of the coupling agent (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)).  The 
reaction proceeded under anhydrous conditions, in the dark for a period of 2-2.5hrs at 
room temperature, pH of 8-9.  The polymer ferrocene conjugate was precipitated with 
10ml Et2O:hexane (2:1), and re-dissolved in 10 ml water with 0.5 % ascorbic acid.  The 
solution was dialysed in Spectra/Por 4 tubing for 1hr against water kept at pH 5-6, and 
subsequently for 24hrs against DI water, pH 6-7.  Freeze-drying of the retentate afforded 
a water soluble brown solid in the yield of 183 mg (61 %), ηinh(H2O) 8 mL g-1.  Analysis 
found: % Fe 2.53% (2.9 %) 
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4.4.3 Polymer conjugation with β-alanine-modified tetramethylmelamine   
Synthesis of macro-monomer, M7 
The intermediate M7 was prepared by the drop-wise addition of 1.894 g (42 mmol) 95 % 
(mass:mass) dimethylamine to 3.688 g (20 mmol) cyanuric chloride in a slightly alkaline, 
pH 7-7.5, dioxane:water solution, at room temperature.  The reaction proceeded for  
48 hrs under these conditions, during which the alkalinity (pH 7-7.5) was maintained by 
the regular addition of sodium hydroxide.  The product, M7, was isolated, following 
alkalification, extraction with three times 20ml portions of ethyl acetate and 
recrystallization from the same solvent following a reduction in volume.  The product 
was isolated as a colourless solid, in a yield of 2.729 g (74%), and a melting point of  
115 -117 0C.   
  1H NMR, δ/ppm: 3.5-3.0 ppm N(CH3)2 6H(6H) 
 
Synthesis of macro-monomer, M8 
The tetramethylmelamine derivative, M8, was prepared by refluxing M7, 0.403 g  
(2 mmol), with 0.445 g (5 mmol) β-alanine in dioxane:distilled water (1:1), under slightly 
alkaline conditions, pH 7-8., by the regular addition of NaOH for a period of 48 hrs.  
Afterwards the product M8, was isolated as a white crystalline material following 
extraction and recrystallization from boiling water.  The product was obtained in a yield 
of 0.169 g (42 %) and characterized by 1H NMR spectrum, measured in D2O at a slightly 
acidic pH.   
 1H NMR, δ/ppm: 3.7-3.5 ppm CH2-CH2-COOH 2H(2H), 3.1-3.0 ppm (CH3)2-N 
6H(6H), 2.5-2.4 ppm NH-CH2-CH2 2H(2H) 
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Copolyaspartamide of β-alanine-modified tetramethylmelamine  
1e*-tr 
1.0 g of M8 was added to 15ml distilled water and the pH of the mixture was adjusted to 
pH 6.5-7.5 and stirred for 30min. Afterwards M8 was isolated by freeze-drying and 
conjugated to a polyaspartamide as follows; 
 
Compound 1e*, 300 mg (0.153 mmol) was dissolved in a 2 ml DMF, to this solution was 
added 77 mg (0.384 mmol) of the pre-treated M8 and 67 mg (0.168 mmol) of the 
coupling agent (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU)).  The reaction proceeded under anhydrous conditions in 
the dark for a period of 2-2.5 hrs at room temperature, and slightly alkaline pH (7-8.5).  
The conjugate was isolated following a series of purification steps which included 
filtering of the suspension, precipitation in a non-solvent, scrupulous washing, aqueous 
dialysis and freeze-drying.  The product was obtained as a colourless, water soluble 
crystalline material, with a yield of 183 mg (61 %) and inherent viscosity of 9 mL g-1.  
The quantity of tetramethylmelamine derivative present was determined by 1H NMR, and 
found to be 8.4 % by mass, when considering the mass of tetramethylmelamine present in 
the of 3-(4,6-bis(N,N-dimethylamino)-1,3,5-triazacyclohexatrien-2-yl) propanoic acid 
polymer conjugate as a percentage of the total mass of the polymer-drug conjugate 
  1H NMR, δ/ppm: 4.7-4.5 ppm Asp CH 10H(10H), 3.2-3.0 ppm CH2-NHCO 
24H(22H), 3.0-2.9 ppm (CH3)2-N-triazine 10H(12H), 2.9-2.5 ppm Asp CH2, 
CO-CH2-CH2 22H(22H), 2.5-2.2 ppm NH-CH2-CH2 24H(20H), 2.2-1.9 ppm 
N-CH3 55H(54H), 1.7-1.5 ppm CH2-CH2-CH2 20H(20H) 
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1f-tr 
1.0 g of M8 was added to 15ml de-ionised water and the pH of the mixture was adjusted 
to pH 6.5-7.5 and stirred for 30 min. Afterwards M8 was isolated by freeze-drying and 
conjugated to a polyaspartamide as follows; 
 
Compound 1f, 300 mg (0.147 mmol) was dissolved in a 2 ml DMF, to this solution was 
added 59 mg (0.294 mmol) of the pre-treated M8 and 64 mg (0.162 mmol) of the 
coupling agent (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU)).  The reaction proceeded under anhydrous conditions in 
the dark for a period of 2-2.5 hrs at room temperature and slightly alkaline pH (7-8.5).  
The conjugate was isolated following a series of purification steps which included 
filtering of the suspension, precipitation in a non-solvent, scrupulous washing, aqueous 
dialysis and freeze-drying.  The product was obtained as a colourless, water soluble 
crystalline material, with a yield of 141 mg (47 %) and inherent viscosity of 7 mL g-1.  
The quantity of tetramethylmelamine present in the conjugate was determined by 1H 
NMR, and found to be 8.7 %, when considering the mass of tetramethylmelamine present 
in the of 3-(4,6-bis(N,N-dimethylamino)-1,3,5-triazacyclohexatrien-2-yl) propanoic acid 
polymer conjugate as a percentage of the total mass of the polymer-drug conjugate 
. 
1H NMR, δ/ppm: 4.7-4.5 ppm Asp CH 8H(10H), 3.7-3.5 ppm CH2-O 
7H(8H), 3.2-3.0 ppm CH2-NHCO 20H(22H), 3.0-2.9 ppm (CH3)2-N-
triazine 8H(12H), 2.9-2.5 ppm Asp CH2, CO-CH2-CH2 21H (22H), 2.5-2.2 
ppm NH-CH2-CH2 22H(20H), 2.2-1.9 ppm N-CH3 54H(54H), 1.7-1.5 ppm 
CH2-CH2-CH2 18H(18H)  
  
111
4.4.4 Polymer conjugation with β-alanine-modified tetramethylmelamine  and 
ferrocenylbutanoic acid 
 
Copolyaspartamide of  β-alanine-triazine and ferrocenylbutanoic acid 
1e*-Fc/tr 
M8, 300 mg was added to 15 ml distilled water and the pH of the mixture was adjusted to 
pH 6.5-7.5 and stirred for 30 min. Afterwards M8 was isolated by freeze-drying and 
conjugated to a polyaspartamide as follows; 
 
Polymer 1e*, 236 mg (0.236 mmol) was dissolved in a 1 ml DMF, to this solution was 
added (0.118 mmol) 32 mg of the ferrocenylbutanic acid and 52 mg (0.130 mmol) of the 
coupling agent (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU)).  The reaction proceeded under anhydrous conditions in 
the dark for a period of 2-2.5 hrs at room temperature and slightly alkaline pH 7-8.5.  To 
this solution was added 47 mg (0.236 mmol) of M8 and 52 mg (0.130mmol) of the 
coupling agent HBTU, in situ, and the reaction continued in the dark for a further 2-2.5 
hrs in the dark at a pH of 7-8.5.  The conjugate was then isolated following a series of 
purification steps which included filtering of the suspension, precipitation in a non-
solvent, scrupulous washing, aqueous dialysis and freeze-drying.  The product was 
obtained as a colourless, water soluble crystalline material, with a yield of 207 mg (69%) 
and inherent viscosity of 7 mL g-1.  The quantity of both iron and the 
tetramethylmelamine present was determined by 1H NMR, and found to be 2.9 % and  
3.4 %, respectively, when considering the mass of iron, and the mass of the 
tetramethylmelamine present in the co-conjugate as a percentage of the total mass of the 
co-conjugate. 
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 1H NMR, δ/ppm: 4.0-4.2 ppm ferrocenyl 3H(4.5H), 3.2-3.1 ppm CH2-NHCO 
23H(22H), 3.1-2.9 ppm (CH3)2-N-triazine 5H(6H),  2.9-2.5 ppm Asp CH2, 
CO-CH2-CH2 21H (22H), 2.5-2.2 ppm NH-CH2-CH2 20H(19H), 2.2-1.9 ppm 
N-CH3 57H(54H), 1.7-1.5 ppm CH2-CH2-CH2 21H(21H)  
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CHAPTER 5 
Conclusion and Future Work 
In this project various water-soluble, biodegradable macromolecular polymer carriers of a 
defined structure were synthesized under meticulous conditions of time, temperature and 
pH.  The carriers synthesized all form part of the polyamide-based family of polymers 
and included; 
• copolyaspartamides, obtained by ring-opening reaction of poly(succinimide) in 
the presence of a mono-functional amine.  
• polyamidoamines, obtained by the Michael-type addition polymerisation of a 
divinyl monomer in the presence of a mono-functional amine 
• polyamides obtained by the base-catalysed ester-amine condensation 
polymerisation between a diester and a diamine 
 
All the polymers were purified under meticulous dialysis conditions, in both 12000 and 
25000 molecular mass cut-off membranes and freeze-dried.  This afforded water-soluble 
solids which were used to investigate various drug models including; the square-planar 
platinum complexes, the organoiron compound, ferrocene and a tetramethylmelamine 
derivative.  
 
The platination agents potassium tetrachloroplatinate (K2PtCl4) and 
diaminocyclohexanediaquaplatinum(II) nitrate (DACH-Pt aq) were anchored to the 
carriers using established methods, which involved co-ordination of the platinum to 
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amino, dihydroxylato or dicarboxylato- ligands present on the polymer chain,  Generally 
the amine bound conjugates exhibited a much higher incorporation of platinum compared 
to the carboxyl, or hydroxyl bound counterparts.  Furthermore for the carboxyl, hydroxyl-
bound conjugates, the platinum content was extremely variable depending on the polymer 
used. 
 
The ferrocene derivative, 4-ferrocenylbutanoic acid was synthesised using established 
procedures and conjugated to the carrier via pendant amino groups situated on the carrier, 
via amidation reaction, using the coupling agent HBTU.  On average the iron contents in 
the conjugate were acceptably high and were similar to percentages obtained previously 
in this laboratory. 
 
The tetramethylmelamine derivative was synthesised using various modified methods and 
conjugated to pendant amino groups present on the carrier, using an amidation reaction.  
Conjugation resulted in a fair degree of drug loading. 
 
Finally there was a single attempt to incorporate both the ferrocene and the 
tetramethylamelamine derivative into the same carrier.  Conjugation proceeded via an 
amidation reaction, preliminary results suggested a fair degree of loading of both the 
ferrocene and the tetramethylmelamine derivative. 
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Future research should address the following questions; 
1. Investigate alternative conjugation procedures to anchor DACH-Pt aq so as to 
reduce the fair degree of variability in platinum content, which exists between 
different dicarboxyl and dihydroxyl containing polymers 
2. Optimise the conjugation procedure required to anchor the tetramethymelamine 
derivative, to increase the drug loading within the carrier 
3. Optimise the conjugation procedure required to anchor both the 
tetramethymelamine derivative and ferrocene on the same carrier 
4. Consider other carboxyl containing drugs e.g. methotrexate (MTX), which could be 
co-conjugated to an appropriate carrier 
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